⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

GBM is serious, but treatment buys meaningful time. Modern therapy extends life significantly and many patients maintain good quality of life during treatment.
Maximal safe resection matters. Removing as much tumor as safely possible improves survival — seek a neurosurgeon experienced with advanced techniques like awake craniotomy.
The Stupp protocol is the standard of care. Temozolomide (TMZ) combined with radiation after surgery is the proven first-line treatment for most GBM patients.
MGMT methylation status predicts chemo benefit. If your tumor has MGMT promoter methylation, temozolomide is more likely to be effective — make sure this test is done.
Tumor treating fields (TTFields) are an option. This wearable device therapy can extend survival when added to standard treatment, though it requires commitment to daily use.
Clinical trials are critical. GBM research is very active, and trials offer access to promising new approaches including immunotherapy and targeted therapies.
Quality of life decisions matter. Every treatment choice should weigh the impact on daily function and what matters most to you — discuss this openly with your team.
Early palliative care helps everyone. Palliative care is about comfort and support alongside treatment, not giving up — it improves both quality and length of life.

▼ Collapse

Understanding Glioblastoma

The brain has two main types of cells: neurons (which handle thinking and signaling) and glial cells (support cells that feed, protect, and maintain the neurons). Glioblastoma is a cancer that starts in a type of glial cell called the astrocyte. It is classified as a grade 4 glioma — the most aggressive grade. Doctors often refer to it as GBM.

In the United States, approximately 12,000 new cases are diagnosed each year according to the Central Brain Tumor Registry of the United States (CBTRUS). Worldwide, glioblastoma accounts for an estimated 150,000–200,000 of the roughly 300,000+ primary malignant brain tumors diagnosed annually (exact GBM figures vary by registry and classification). This relatively small patient population has significant implications for treatment development and research funding.

What "average survival" actually means Published averages of 12 to 18 months include patients of all ages, health statuses, and treatment access levels. A younger patient in good general health, treated at a major cancer center with an active research program, may have a different outlook from that broad average, though individual outcomes vary widely and cannot be predicted. Population-based data report a five-year relative survival of approximately 6 to 8 percent; long-term survival beyond ten years occurs in fewer than 2 percent of patients. These are rare outcomes, not expectations.

The survival numbers for glioblastoma are sobering, and there is no honest way around that. But there are important things to understand about what statistics can and cannot tell you about your situation:

An average is not a prediction. A “median survival of 15 months” means half of a large, diverse group lived longer and half shorter — it is a description of a population, not a forecast for an individual. No statistic can tell you where in that range you will fall.
The averages lump very different people together. They include patients of all ages, fitness levels, tumor types, and access to specialized care. Several factors are associated with better outcomes: younger age, good day-to-day function, more complete surgical removal, an MGMT-methylated tumor, and treatment at a center with an active brain-tumor program. These don’t guarantee anything, but they mean the broad average may not be the right reference point for a given person.
The numbers you find online are often out of date. Published survival figures reflect patients treated years ago, before current techniques and trials. They cannot capture the benefit of an option that did not exist when those patients were treated.
Statistics describe the past; they do not account for you. They cannot factor in your specific tumor biology, how you respond to treatment, or a clinical trial you might join.

Many people find a middle path most livable: take the disease seriously enough to make the important decisions and plans now (legal documents, priorities, treatment choices), while refusing to let a median number define how you live each day. Ask your team about your specific prognostic factors rather than the generic average — and tell them how much detail you want, because some people want every number and others do not.

Why Glioblastoma Is Especially Difficult

Three features of this disease drive treatment decisions and explain why progress has been slower than in many other cancers:

Invisible spread. By the time GBM appears on a scan, microscopic tumor cells have already extended into surrounding brain tissue. Even when a surgeon removes everything visible, some cells remain. This is why radiation and chemotherapy follow surgery in nearly every case.
The blood-brain barrier. A tightly sealed cellular layer lines the brain's blood vessels, blocking most drugs from reaching the tumor at useful concentrations. Many cancer drugs that work elsewhere in the body are ineffective against brain tumors because they cannot cross this barrier. The section below on the blood-brain barrier is devoted to this problem.
Intra-tumor diversity. Different parts of the same GBM can behave like different diseases. A drug that kills most cells may leave behind a resistant subpopulation that regrows. This is why treatment plans typically combine multiple approaches.

Molecular Markers: The Map That Personalizes Treatment

A piece of the tumor removed during surgery is sent to a laboratory for molecular testing. These results are among the most important pieces of information in the entire treatment plan. They predict how the tumor will respond to treatment and determine which clinical trials the patient may be eligible for.

Discuss all results with your medical team. The information below describes what each marker means in general. Your medical team can explain what each result means for your specific situation.

Key Markers to Request

MGMT promoter methylation — Predicts temozolomide response. Methylated tumors respond significantly better to chemotherapy and unlock an intensified regimen called CeTeG.
IDH1 and IDH2 mutation — If mutated, the diagnosis is technically a different disease (grade 4 astrocytoma) with a better prognosis and different treatment options.
BRAF V600E mutation — Rare in adult GBM, but if present opens a targeted drug combination with FDA approval across solid tumors.
NTRK fusion — Also rare, but opens specific targeted therapies with broad FDA approval.
MTAP deletion — Present in about 15% of GBMs; creates a vulnerability that experimental drugs in clinical trials can target.
H3 K27M mutation — Changes the WHO diagnosis to diffuse midline glioma. The FDA granted accelerated approval (2025) to dordaviprone (Modeyso) for patients aged 1 and older with H3 K27M-mutant diffuse midline glioma that has progressed after prior therapy. Continued approval depends on confirmatory trial results. Worth specifically requesting H3 K27M testing if not included in the standard panel.
Tumor mutational burden, microsatellite instability, mismatch repair status — Determine whether the tumor is "hypermutated," which may make immune checkpoint therapies more effective.
Surface markers (B7-H3, IL13Rα2, EGFRvIII, HER2) — Not always tested routinely but determine eligibility for several CAR-T cell therapy trials.
CMV (cytomegalovirus) status — Research suggests many GBMs show signs of CMV inside tumor cells, opening a conversation about antiviral add-on therapy.

The standard commercial panels for comprehensive testing include FoundationOne CDx, Tempus xT, and Caris Molecular Intelligence. If the treating center's in-house panel is more limited, a supplemental send-out can usually be arranged.

The molecular report can look like alphabet soup. Here is what the most important results actually mean for treatment and outlook — though your medical team should always explain your specific results in context:

IDH status is the most fundamental result. “IDH-wildtype” is the standard glioblastoma. “IDH-mutant” is technically a different, generally slower-growing disease (now called grade 4 astrocytoma) with a meaningfully better outlook and a different treatment menu — an important distinction worth confirming.
MGMT methylation predicts how well the chemotherapy temozolomide is likely to work. “Methylated” means the chemo tends to work better and the outlook is somewhat more favorable; it can also open an intensified regimen discussion (CeTeG). “Unmethylated” means standard chemo is less effective — which makes clinical trials a higher priority. Either way, the test guides the plan.
Rare “actionable” markers (BRAF V600E, NTRK fusion, H3 K27M, high tumor mutational burden) are uncommon but worth testing for, because each can open a specific targeted drug or trial that would not otherwise be considered.
Surface markers (EGFRvIII, IL13Rα2, B7-H3, HER2) don’t change standard treatment but determine eligibility for certain CAR-T cell therapy trials.

Two practical points: make sure comprehensive testing is actually ordered (ask specifically about IDH, MGMT, and a broad panel), and ask your oncologist, “Given my molecular results, does anything change — and am I eligible for any trials because of them?” These results are among the most important information in your whole treatment plan.

The molecular profile is worth more than any supplement decision. The branches in the molecular decision tree change survival meaningfully. Ensure this conversation with the oncologist happens early and thoroughly.

The First Weeks After Diagnosis

The period between surgery and the start of radiation/chemotherapy — typically two to six weeks — is the most time-sensitive window in GBM care. Several decisions made during this window can open or close options for the future.

What Matters Most Right Now

Ensure the standard care plan is well-organized and starting on time (radiation typically begins 2-6 weeks after surgery)
Get comprehensive molecular testing ordered and results reviewed
Start the second-opinion process at a major brain tumor center
Begin Optune (Tumor Treating Fields) insurance authorization — approval often takes weeks
Complete legal documents (will, advance directive, healthcare power of attorney) while cognition is fully intact

A note on urgency. The treatment clock is not as urgent as a heart attack, but more urgent than most cancers. This window defines how much time exists for second opinions, additional testing, and clinical trial screening.

Glioblastoma care involves a whole team, and knowing who handles what helps you direct questions to the right person and recognize when someone is missing from your care:

Neurosurgeon — performs the operation and aims for maximal safe removal; addresses surgical questions and tissue/biopsy issues.
Neuro-oncologist — the “quarterback” of medical treatment: chemotherapy, molecular-result interpretation, clinical trials, and overall coordination. A neuro-oncologist (a brain-tumor specialist) is different from a general oncologist and is worth seeking out.
Radiation oncologist — plans and delivers the radiation course and manages its side effects.
Neuropathologist — analyzes the tumor tissue and produces the molecular profile that drives the plan.
Palliative care team — helps with symptoms, decision-making, and support from early on, alongside active treatment.
Rehabilitation therapists (physical, occupational, speech) and neuropsychology — help recover and adapt to any changes in movement, function, or thinking.
Nurse navigator / social worker — often the most useful day-to-day contact for scheduling, insurance, trial logistics, and connecting you to resources.

At a major brain-tumor center, these specialists often discuss complex cases together at a “tumor board.” It is reasonable to ask whether your case has been reviewed by one. Knowing each role also tells you whom to call: surgical-site questions to neurosurgery, chemo and trial questions to neuro-oncology, radiation side effects to radiation oncology — and the nurse navigator when you’re not sure.

Standard Treatment: The Foundation

Everything else in this guide builds on one principle: the treatments with the strongest evidence of extending life in GBM are the standard treatments. Experimental options, repurposed drugs, and clinical trials are considered in addition to standard care, never as replacements.

The standard sequence is:

Surgery — Maximum safe removal of the tumor
Chemoradiation — Six weeks of radiation combined with daily temozolomide (the Stupp protocol)
Recovery period — Typically four weeks
Maintenance chemotherapy — Several months of temozolomide (or CeTeG for MGMT-methylated tumors)
Tumor Treating Fields (Optune) — Wearable device used alongside maintenance chemotherapy

Important safety note. If anyone suggests that standard care is harmful or unnecessary and that some alternative protocol can replace it, exercise extreme caution. Standard care is imperfect, but it has the strongest evidence of any approach by far. Build on it. Do not abandon it.

Many GBM decisions do not have a single “right” answer. They involve trade-offs between how much time a treatment might add, what it costs in side effects and daily burden, and what matters most to you. Understanding how to think through these choices makes you a genuine partner in them.

Ask three questions of any treatment: What is the realistic benefit (and how strong is the evidence)? What is the burden — side effects, time, travel, recovery? And does it fit my goals and values? A treatment that adds modest time but costs many weeks in the hospital may be right for one person and wrong for another.
Distinguish proven from promising. Standard care (surgery, chemoradiation, TTFields) has the strongest evidence. Clinical trials offer access to promising approaches but uncertain benefit. Off-label and alternative options range from reasonable-to-discuss to unsupported. A good neuro-oncologist will help you place each option on that spectrum honestly.
Quality of life is a legitimate goal, not “giving up.” Choosing a less aggressive path to protect function, independence, or time at home is a valid, values-based decision — not a failure. So is choosing maximal treatment. The “best” choice is the one aligned with what you want your time to look like.
Get a second opinion early, especially at a brain-tumor center. For a disease this complex, a second opinion at a high-volume center is standard practice, not distrust of your doctor — it can confirm the plan, surface trial options, or change the surgical approach. The time to do this is early, before chemoradiation, when the most options are open.
Bring your priorities into the room. Tell your team what you care about most — more time at any cost, more good days, staying out of the hospital, a specific event you want to reach. They can only tailor recommendations to goals they know about.
You can change your mind. Decisions made now are not irreversible commitments. As the situation evolves, it is appropriate to revisit what makes sense.

Palliative care (a team focused on comfort, symptom control, and decision support) can help with exactly this kind of values-based decision-making from early in the illness — alongside active treatment, not instead of it.

Surgery: Understanding What Was Done

The first treatment for nearly every newly diagnosed GBM is surgery. The goal is "maximal safe resection" — removing as much tumor as possible without damaging critical brain functions. Extent of resection is the single most important modifiable surgical factor.

Questions to Discuss with the Surgical Team

What was the extent of resection? Was a post-operative MRI performed within 24-72 hours?
Was 5-ALA fluorescence guidance (Gleolan) used? (This substance makes tumor cells glow under special surgical lighting)
Was extra fresh tumor tissue preserved for potential future personalized treatments? Was any tissue snap-frozen?
What molecular tests have been ordered on the tissue?
Is there enough tissue available to send to outside laboratories for expanded testing?

If tissue questions were not addressed at surgery, most items can still be investigated afterward — the original tissue block at the hospital pathology lab is typically usable for additional testing for months to years.

For most people, recovery from a planned glioblastoma resection is more manageable than they fear. Knowing the general arc helps reduce anxiety, though every patient and tumor location is different — your surgical team’s specific guidance always takes priority.

The hospital stay is often just a few days for an uncomplicated resection, frequently starting with a night of close monitoring. A post-operative MRI within 24–72 hours checks how much tumor was removed.
Early symptoms commonly include fatigue, headache (usually controlled with medication), and some scalp tenderness or swelling around the incision. These typically improve over days to weeks.
Steroids and seizure medicine are often used around surgery — steroids to control swelling (then tapered to the lowest effective dose) and an anti-seizure medicine in many cases. Do not adjust these on your own.
New or temporary deficits: Depending on tumor location, some people have temporary worsening of weakness, speech, or other functions right after surgery from swelling, which often improves. Rehabilitation (physical, occupational, speech therapy) helps recovery — ask whether it’s needed.
Activity: Most people are walking soon after surgery. Lifting, driving, and return to work are restricted at first — ask for specific timelines, especially about driving, which is also affected by seizure laws in your area.
The timeline to next treatment: Radiation and chemotherapy usually begin about 2–6 weeks after surgery, allowing the incision to heal. This window is also when molecular results return and second opinions and trial screening happen.

When to call urgently after surgery: fever, worsening or severe headache, increasing drainage/redness/swelling at the incision, a new seizure, or new weakness, confusion, or speech trouble. When in doubt, call the surgical team.

Chemoradiation: The Stupp Protocol

Named after Dr. Roger Stupp, whose landmark 2005 clinical trial established its value, this is a six-week course of radiation combined with daily temozolomide chemotherapy.

What to Expect

Radiation: 60 Gray delivered in 30 daily fractions over 6 weeks (Monday through Friday). Each session takes 15-30 minutes.
Temozolomide: A pill taken every day (including weekends) during radiation. It crosses the blood-brain barrier and damages DNA in dividing cancer cells.

Common Side Effects

Fatigue — Builds gradually, most pronounced in the final weeks and the month or two after.
Hair loss — In the radiation area; may be permanent in that specific area.
Nausea — Usually well controlled with ondansetron (Zofran) taken before each temozolomide dose.
Blood count changes — Regular monitoring is essential. The medical team will adjust doses if counts drop.

If MGMT Is Methylated: The CeTeG Discussion

For patients whose tumor is MGMT-methylated, an intensified regimen called CeTeG adds the chemotherapy drug lomustine to the standard protocol. In the published CeTeG/NOA-09 randomized trial (Herrlinger et al., Lancet 2019; 141 randomized, 129 treated), MGMT-methylated patients on the lomustine-temozolomide combination had a median overall survival of approximately 48 months, versus approximately 31 months in patients on temozolomide alone. The trial population had selection criteria (age 18–70, Karnofsky ≥70) that may not match every individual patient. A subsequent real-world multicenter analysis reported median survival closer to 34 months. CeTeG has not yet changed standard-of-care guidelines and remains investigational; it may involve increased toxicity compared to standard temozolomide alone. Individual results vary substantially. Discuss with your neuro-oncologist whether the regimen, side-effect profile, and your specific clinical situation make this option appropriate.

Essential Supportive Care During Chemoradiation

PCP prophylaxis — Preventive antibiotics (typically trimethoprim-sulfamethoxazole) to prevent a serious lung infection. Standard of care during chemoradiation and should continue through maintenance temozolomide in patients who remain on steroids. Discuss duration with your medical team.
Anti-nausea medication — Ondansetron before each temozolomide dose.
Blood count monitoring — Weekly CBC during chemoradiation; before each maintenance cycle.
Blood clot awareness — GBM patients have a 20-30% rate of venous thromboembolism in the first year. Watch for one-sided leg swelling, sudden shortness of breath, or chest pain.
Acid reduction discussion — Recent research has suggested that certain proton pump inhibitors (omeprazole, pantoprazole) may be associated with less favorable outcomes. Discuss alternatives such as famotidine with your medical team.

Tumor Treating Fields (Optune)

Optune is a wearable device that delivers low-intensity alternating electrical fields through pads on the scalp. These fields interfere with how cancer cells divide without affecting normal brain function. A randomized trial showed meaningful improvement in overall survival when added to maintenance chemotherapy.

Wear time appears to matter. A post-hoc subgroup analysis of the pivotal trial (EF-14) reported that patients using the device for more than 90% of the time (about 22 hours/day) had longer median survival than those using it less than 75% of the time. Because this was a post-hoc analysis (not the primary endpoint), the finding is suggestive rather than definitive, and individual results vary. Maximizing comfortable, tolerable wear time — within the limits the medical team and the manufacturer's instructions recommend — is generally the practical goal.

The Compliance Data That Changes How to Think About Optune

The EF-14 randomized trial (695 patients, newly diagnosed GBM, published in JAMA 2017) established Optune as a survival-extending addition to maintenance temozolomide. Overall results: median OS 20.9 months (Optune + TMZ) versus 16.0 months (TMZ alone) — a statistically significant difference (HR 0.63). Five-year survival was 13% versus 5%. This is the trial that earned FDA approval.

But within the trial, a post-hoc compliance analysis revealed a dose-response relationship that reframes how seriously to take the daily wear target:

Patients wearing Optune more than 90% of the time (approximately 21–22 hours/day): median OS 24.9 months
Patients wearing it 75–90% of the time: median OS approximately 21.1 months
Patients wearing it less than 50% of the time: median OS 13.5 months

The difference between 75% and 90% wear time is approximately 4 months of median survival in this analysis. This was a post-hoc analysis — not a pre-specified comparison — so it cannot prove causation. But the dose-response pattern across compliance quintiles is consistent and biologically plausible (the device can only disrupt tumor cell division while it is actually delivering fields). Most neuro-oncologists treat maximizing wear time as the primary modifiable variable in patients using Optune.

Practical Compliance Tips

Get a second set of arrays. While one set of pads is on your head, the other is charging. This eliminates downtime during battery swaps and allows pad changes without removing power from the device. Ask your Novocure representative to ensure you have a second set from the start.
Schedule showers for the same time each morning. Device removal for showers and scalp care is the largest source of daily wear-time loss. Building it into a consistent morning routine — shower, dry, re-apply arrays — minimizes unplanned removal throughout the day.
Scalp care is the key to long-term compliance. Contact dermatitis under the adhesive pads is the most common reason patients reduce wear time. Preventive strategies: rotate array positions 1–2 cm at each pad change (your Novocure device maps allow this), use fragrance-free products on the scalp, apply a thin layer of barrier cream to irritated areas only (not under adhesive zones), and shave the head every 3–5 days as directed. At the first sign of significant skin breakdown, call your medical team — untreated scalp wounds can become infected and require temporary device removal.
Travel and activity are possible. Optune is allowed on commercial flights (carry as medical device, not in checked luggage). The device works in hospitals, outpatient settings, and in most daily activities. The battery pack (approximately 3 lbs) can be carried in a shoulder bag or backpack. Novocure provides dedicated patient support for any technical questions: 1-855-281-9301.
The three-pound device is manageable — plan how to carry it. Most patients adapt to carrying the battery pack within days to weeks. A soft backpack, messenger bag, or dedicated Novocure carry bag all work. Planning how you will manage it in your daily routine before the device arrives reduces friction on the first day.

Additional Practical Details

Target at least 18 hours per day of wear time — ideally 22+ hours. The device works only while it is on, and post-hoc analyses suggest a dose-response relationship between wear time and outcomes. Plan daily routines (sleeping, working, errands) around keeping the device on; remove it only for bathing and pad changes.
Requires shaving the head every 3-5 days for pad adhesion
Scalp care is critical. Contact dermatitis under the pads is the most common reason patients reduce wear time. Use gentle, fragrance-free skin products; rotate pad placement as the device maps allow; let the Novocure support team adjust layouts if irritation develops; and report any breakdown or infection to the medical team promptly
The device weighs about three pounds with a battery carried in a shoulder bag
Insurance authorization: Most insurance plans cover Optune, but prior authorization often takes 2–4 weeks. Start the process immediately after surgery. Novocure (the manufacturer) provides dedicated patient support for training, supplies, insurance navigation, and a patient assistance program for financial hardship: 1-855-281-9301.

Steroid Management

Dexamethasone is commonly used to reduce brain swelling around the tumor. It is effective but carries significant side effects with prolonged use: muscle wasting, mood changes, increased infection risk, elevated blood sugar, insomnia, and weight gain. Long-term steroid use may also interfere with certain treatment strategies.

The practical goal is the lowest effective dose. Many patients can reduce their dose substantially over time, and some can taper off entirely. Discuss the taper plan with your medical team — do not adjust steroid doses independently, as sudden changes can cause serious problems.

Why Steroid Minimization Is a Treatment Strategy, Not Just Side-Effect Management

The rationale for minimizing dexamethasone goes deeper than avoiding side effects. Two mechanisms make high-dose steroids directly harmful to GBM outcomes:

The glucose-tumor connection. GBM cells preferentially metabolize glucose (the Warburg effect — cancer cells consume glucose at rates far exceeding normal brain tissue even in the presence of oxygen). Dexamethasone reliably raises blood glucose, sometimes dramatically — steroid-induced hyperglycemia is one of the most common complications of prolonged steroid use. Chronically elevated blood glucose provides a constant fuel supply that benefits tumor cells. This is one of the mechanistic rationales for the ketogenic diet approach (reducing glucose availability) and reinforces why blood glucose control during steroid use matters beyond just diabetic complications.

The immune suppression problem. Corticosteroids suppress T-cell activity and broadly dampen immune function. This is by design when the goal is reducing brain inflammation — but it is precisely the wrong direction for anyone hoping to benefit from immunotherapy. Checkpoint inhibitors (pembrolizumab, nivolumab), CAR-T cell therapies, and vaccine-based approaches all depend on activating the immune system against the tumor. Starting immunotherapy on high-dose steroids is functionally like pressing both the accelerator and the brake simultaneously. Most immunotherapy trials exclude patients on ≥4–8 mg dexamethasone daily for this reason. Reducing steroid dose to the lowest necessary level is a prerequisite for future immunotherapy eligibility, not just a quality-of-life goal.

Boswellia as a Steroid-Sparing Adjunct

A small randomized trial by Kirste and colleagues (published in Cancer 2011) enrolled 44 patients with primary or metastatic brain tumors undergoing radiotherapy and compared standardized boswellia extract (60% AKBA content, 4×600 mg/day = 2,400 mg/day) against placebo. Boswellia-treated patients showed a statistically significant reduction in FLAIR-measured peritumoral edema on MRI compared to placebo. Whether this translates to clinical benefit, reduced steroid need, or improved outcomes for any individual GBM patient is unknown — this is a small, single trial, and boswellia is a dietary supplement without FDA approval for any oncology indication.

However, the biological plausibility is reasonable (boswellic acids inhibit 5-lipoxygenase, reducing leukotriene-driven inflammation that contributes to peritumoral edema), the side-effect profile appears modest, and the intervention is low-cost. Some neuro-oncologists are willing to discuss it for patients who are having difficulty tapering steroids. Discuss specifically: the AKBA-standardized extract (not generic boswellia), the dose (2,400 mg/day as studied), potential drug interactions, and whether any contraindications apply to your situation.

A Note on Proton Pump Inhibitors (PPIs)

Many patients on steroids are placed on a proton pump inhibitor (PPI) such as omeprazole or pantoprazole to protect the stomach. Recent research has raised a concern: PPIs can inhibit autophagy (the cellular self-digestion pathway that some chemotherapy drugs, including temozolomide, partially rely on to kill cancer cells). Several retrospective studies in oncology have suggested worse outcomes in patients on PPIs during chemotherapy, though the evidence is not conclusive and confounding by disease severity is possible.

A practical alternative: famotidine (Pepcid), an H2 receptor blocker, provides effective acid suppression through a different mechanism that does not significantly affect autophagy. If your medical team recommends acid suppression for stomach protection during steroid use, asking about famotidine as an alternative is a reasonable conversation. Do not stop a prescribed PPI without discussing it with your team.

Symptoms That Warrant Calling Your Team About Steroids

The following signs should prompt a call to your medical team rather than self-adjusting the steroid dose:

Blood glucose readings above 250 mg/dL, or symptoms of high blood sugar (excessive thirst, frequent urination, blurred vision)
Signs of infection: fever, unusual wound redness, drainage, or slow-healing skin
Severe mood changes: agitation, paranoia, depression severe enough to interfere with daily function
New or significant muscle weakness, especially difficulty rising from a low chair or climbing stairs (steroid myopathy, which develops over weeks to months)
Persistent insomnia unresponsive to timing adjustments
Any sudden worsening of headache, new neurological deficit, or confusion (these may indicate that steroid tapering was too fast and brain swelling has returned — this is a medical urgency, not a routine callback)

When to contact your medical team about steroids: Call if you develop a blood sugar reading above 250 mg/dL (or symptoms of high blood sugar: excessive thirst, frequent urination), signs of infection (fever, unusual redness, or slow-healing wounds), severe mood changes (agitation, confusion, or depression that interferes with daily function), new muscle weakness especially in the hips or thighs (difficulty rising from a chair), or persistent insomnia that does not respond to sleep hygiene measures. These can often be managed with dose adjustment or supportive medications.

Seizure Medications

Many GBM patients experience seizures at some point. Levetiracetam (Keppra) is the most common first choice due to its effectiveness and fewer drug interactions with chemotherapy. However, in approximately 10-20% of patients, it can cause mood changes, irritability, or anxiety. If this occurs, discuss alternatives such as brivaracetam or lacosamide with your medical team.

The Blood-Brain Barrier Problem

The blood-brain barrier (BBB) is the single biggest hidden obstacle in GBM treatment. Understanding it changes how to evaluate every drug claim and treatment recommendation.

Most cancer drugs developed in the last thirty years work well against tumors elsewhere in the body but cannot reach brain tumors at useful concentrations. The BBB tends to be partially broken down in the tumor bulk (which is why contrast dye shows up on MRI) but remains intact in surrounding tissue where the most dangerous infiltrating cells hide.

Three Strategies for Getting Around the BBB

A small number of cancer drugs cross the BBB on their own. Temozolomide is the prime example. Other drugs with reasonable BBB penetration include lomustine, mebendazole, and some newer targeted therapies. Many drugs that barely cross (pembrolizumab, carboplatin, most antibody-based drugs) need to be paired with a delivery strategy.

Low-intensity focused ultrasound with microbubbles: Tiny gas-filled microbubbles are infused intravenously. A focused ultrasound beam causes them to vibrate and gently push apart BBB cells for several hours, allowing drugs to flood in. Available as an implantable device (SonoCloud-9) or non-invasive transcranial systems.

Laser interstitial thermal therapy (LITT): Uses heat from a laser fiber to ablate tumor. As a side effect, opens the BBB in surrounding tissue for weeks afterward. This is why LITT combined with immunotherapy has shown some of the strongest recent results in recurrent GBM.

Convection-enhanced delivery (CED): Catheters placed surgically pump drugs directly into brain tissue.

Implanted brachytherapy (GammaTile): Biodegradable tiles loaded with radioactive seeds placed in the surgical cavity, delivering continuous local radiation.

The critical question for any treatment: How does this drug actually reach the tumor? If a treatment does not cross the BBB on its own, is not paired with a BBB-opening technology, and is not delivered directly into the brain, it is unlikely to work regardless of what laboratory data show.

Three Phases of Treatment

Phase 1: Immediate (Post-Surgery through Start of Chemoradiation)

Theme: Confirm what surgery achieved, establish molecular profile, prepare standard treatment backbone, add low-risk supportive layers. Typically lasts 2-6 weeks.

Phase 2: Short-Term (Months 1-3)

Theme: Layer additional strategies on top of standard chemoradiation. Match targeted therapies to molecular profile. Begin clinical trial conversations. Maintain Optune compliance above 90%.

Phase 3: Medium-Term (Months 3-9+)

Theme: Maintain treatment pressure. Monitor carefully. Write the recurrence playbook before recurrence happens. Pre-contact major centers and international options so logistics are not starting from zero if needed.

The First Seven Days: A Day-by-Day Checklist

The days immediately after a GBM diagnosis are overwhelming. Every hour feels urgent, yet it is hard to know what actually matters most right now. This checklist identifies the highest-leverage actions in the first week — roughly in order of when they should happen. Not every item is possible in every situation, but knowing what exists means you can ask the right questions and delegate effectively.

Designate a medical advocate first. One person — a spouse, adult child, sibling, or close friend — should track these tasks, attend appointments, and take notes. Two people hearing the same conversation retain dramatically more than one. The patient should not be coordinating all of this alone while recovering from brain surgery.

Days 1–2: In the Hospital After Surgery

Confirm what tissue was preserved. Before surgery ideally, the team should have been asked to snap-freeze fresh tumor tissue in addition to the standard formalin-fixed paraffin-embedded (FFPE) block sent to pathology. If you are reading this after surgery, ask now: “Was fresh-frozen tumor tissue preserved in addition to the pathology block?” The FFPE block enables standard molecular testing. Fresh-frozen tissue enables research protocols, organoid drug screening, and dendritic cell vaccine programs that require living material. Neither can be retroactively corrected — knowing now what was preserved shapes what future options are open.
Confirm comprehensive NGS has been ordered — not just MGMT. Many hospitals run a limited panel by default. Ask which laboratory is processing the tissue and what panel was ordered. The minimum comprehensive panel includes: MGMT promoter methylation, IDH1/IDH2, BRAF V600E, NTRK fusions, MTAP deletion, H3 K27M, tumor mutational burden (TMB), mismatch repair status (MMR), and surface markers (EGFR, EGFRvIII, IL13Rα2, B7-H3, HER2). Two commercial platforms that cover most of this are FoundationOne CDx (Foundation Medicine) and Tempus xT (Tempus Labs). If your hospital’s default panel is narrower, ask whether a send-out to one of these labs is possible from the existing pathology block. Results take 2–3 weeks. Without them, treatment decisions are made with incomplete information.
Request CMV staining on the tumor tissue. Ask the pathologist to add cytomegalovirus (CMV) immunostaining to the tissue evaluation. This is a low-cost add-on that tests whether the tumor shows CMV activity — a relevant data point for the antiviral strategy discussion (see Repurposed Drug Candidates). It is most reliably done on the original specimen at initial processing.
Get the post-operative MRI report. A scan within 24–72 hours of surgery is standard. Request a copy of the radiology report. Note what it says about extent of resection: gross total resection (GTR), near-total, subtotal, or biopsy-only. This is a key prognostic variable and affects future surgical planning.
Start Optune insurance authorization immediately. This process takes 2–4 weeks and must complete before Optune can be prescribed after chemoradiation. Ask your oncology nurse coordinator to initiate it now, or call Novocure directly at 1-855-281-9301. Post-hoc compliance data from the EF-14 trial shows patients wearing Optune more than 90% of the time (21+ hours/day) had a median overall survival of 24.9 months versus 13.5 months for those wearing it less than 50% of the time. Starting the authorization process before chemoradiation begins is the only way to keep this option available without delay.

Days 3–5: Before or Just After Hospital Discharge

Request a neuro-oncology consultation before leaving the hospital. In some systems, the neurosurgical team manages all post-operative care without a formal neuro-oncology visit. The neurosurgeon operates; the neuro-oncologist designs the treatment plan. These are different specialties and you need both. If your surgery was at a regional hospital without neuro-oncology, the first visit to a major cancer center neuro-oncologist should happen as soon as possible — in parallel with local surgeon follow-up, not instead of it.
Request physical therapy and occupational therapy evaluations. If there is any new or worsening weakness, speech difficulty, balance problem, or coordination issue after surgery, ask for PT/OT evaluations before discharge. Post-operative rehabilitation can meaningfully accelerate functional recovery. If discharged before these happen, ask for outpatient PT/OT referrals.
Document the steroid taper plan in writing. Ask your medical team: what dose of dexamethasone are you on now, what is the tapering schedule, and what symptoms would prompt them to change it? Write down the answers. Steroids are necessary to control brain swelling initially, but their long-term effects on blood glucose, immune function, and muscle create real problems. The goal is to minimize them to the lowest effective dose as soon as clinically safe. (See the expanded steroid section for why this matters beyond just side effects.)
Collect all your records before leaving. Request copies of: the operative report, the post-operative MRI report, the initial pathology report (even if molecular results are pending), the discharge summary, and the complete medication list. These are required at every specialist consultation and second opinion. Keep them in one folder that your medical advocate can also access.

Week 1 (Days 5–7): Home and Active Planning

Contact Ivy Brain Tumor Center for Phase 0 trial eligibility screening. The Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix (602-406-8605) runs the largest Phase 0 brain tumor trial program in the world. Phase 0 trials test whether a drug actually reaches the tumor at therapeutic concentrations before committing to a full treatment course — uniquely rational for a disease defined by the blood-brain barrier problem. The consultation is often free and frequently surfaces options not available at the patient’s local center. Call in Week 1, while the most options are still open.
Submit a second-opinion request to a major brain tumor center. You have 2–6 weeks between surgery and the start of chemoradiation. Use this window. Send imaging and pathology reports to one or more of: Huntsman Cancer Institute (801-585-7800), MD Anderson (877-632-6789), Dana-Farber (877-442-3324), UCSF Brain Tumor Center (415-353-2966), or Duke Tisch Brain Tumor Center (919-684-5301). A second opinion at a high-volume center frequently identifies trial eligibility, alternative surgical approaches, or additional molecular testing. Do not wait until recurrence to establish a relationship with a major center.
Begin planning for ketogenic or modified Atkins diet if your team approves. The keto flu — fatigue, headache, and irritability during initial carbohydrate restriction — typically hits days 3–7 after starting. Planning now, before chemoradiation, means navigating the adaptation period during recovery rather than during active treatment side effects. Ask your oncology team for an oncology dietitian referral. If strict keto is not feasible, modified Atkins (moderately low carbohydrate) or time-restricted eating are reasonable alternatives. (See the Diet and Metabolic Strategy section.)
Ask about cancer rehabilitation. At Huntsman Cancer Institute, the POWER (Providing Oncology Wellness and Exercise Rehabilitation) program provides individualized exercise prescriptions. Exercise during GBM treatment is associated with better muscle mass preservation, reduced fatigue, lower blood glucose, and improved mood. Ask your oncology team: “Can I get a referral to cancer rehabilitation or an exercise prescription?”

Weeks 2–3: Legal, Logistical, and Clinical Planning

This is the most important window for legal documents. Brain tumor and steroid use can affect cognition over time. Weeks 2–3, before chemoradiation fatigue begins, is the window. This is not about giving up — it is about protecting your family regardless of how the course goes.

Complete advance directive and healthcare power of attorney. The advance directive specifies what medical interventions you want or do not want if you cannot speak for yourself. The healthcare POA designates who makes decisions on your behalf. Complete both. Review with your medical team what specific decisions might arise for a GBM patient (resuscitation, intubation, ICU transfer, hospice transition).
Review or create a will and financial power of attorney. Update beneficiary designations on financial accounts, retirement accounts, and life insurance. A financial power of attorney designates someone to handle financial decisions if the patient is incapacitated. An estate attorney can complete all of these in one or two appointments.
Designate one primary medical advocate. This person attends all appointments, takes notes, is authorized to communicate with the medical team, and coordinates the caregiver network. Set up a shared communication platform — CaringBridge or Lotsa Helping Hands — to coordinate practical help (meals, transportation, childcare, errands) without the patient or primary advocate managing it all.
Begin clinical trial screening in earnest. Bring the following NCT numbers to your first or second neuro-oncology appointment: NCT03970447 (GBM AGILE platform trial — available at many centers), NCT06388733 (Gliofocus — especially for MGMT-unmethylated tumors), NCT06556563 (EF-41/KEYNOTE D58 — Optune plus pembrolizumab, entered after chemoradiation), and NCT05708352 (DIET2TREAT — randomized ketogenic diet trial). Ask which of these you qualify for. Some trials require enrollment before chemoradiation starts.

The most common thing families say afterward: “We didn’t know what we should have been doing in those first weeks.” This checklist is designed to close that gap. Not every item will be possible in every situation. Do what you can. Knowing what the options are — even those you cannot act on — means you are making informed decisions rather than missing them by default.

Pre-Chemoradiation Action Checklist

The items below cover work that ideally happens during the window between surgery and chemoradiation. Some can be done by family members on the patient's behalf.

Right Away
Confirm comprehensive molecular testing has been ordered (MGMT, IDH, BRAF V600E, NTRK fusions, MTAP, H3 K27M, TMB, mismatch repair, surface markers)
Right Away
Request CMV staining on the tumor tissue
Right Away
Initiate Optune insurance authorization
Right Away
Get post-operative MRI report, operative report, and tissue preservation details
Within First Week
Arrange PCP prophylaxis for upcoming chemoradiation
Within First Week
Ask about oncology dietitian referral; discuss glucose-ketone monitoring with medical team
Within First Week
Submit second-opinion request to a major brain tumor center
1-2 Weeks
Discuss repurposed drug options with neuro-oncologist
1-2 Weeks
Discuss steroid taper plan
Within 2 Weeks
Begin clinical trial screening
Within 2 Weeks
Ask medical team about checking baseline vitamin D level (corticosteroid use can impact vitamin D levels)
2-3 Weeks
Complete will, advance directive, and powers of attorney
2-3 Weeks
Designate primary medical advocate; set up caregiver and transportation plan
Before Treatment
Confirm anti-nausea plan and PCP prophylaxis are in place; baseline labs complete

Diet and Metabolic Strategy

GBM cells depend heavily on glucose for energy. Normal brain cells can switch to using ketones (produced when carbohydrates are restricted), but tumor cells are less flexible. The theoretical opportunity is to reduce glucose supply and create metabolic pressure on the tumor while normal cells function on ketones.

Evidence framing. Ketogenic therapy alongside standard care is mechanistically plausible, with encouraging early signals in some published studies. However, it has not yet been proven to extend survival in large randomized trials — notably, the ERGO2 randomized trial did not meet its primary endpoint of improved progression-free survival. The approach is best understood as a theoretical adjunct currently under active study (see the DIET2TREAT trial), not an established therapeutic intervention. Always discuss dietary changes with your medical team before implementing them.

Practical Implementation Points

Work with an oncology dietitian experienced with ketogenic protocols
Target less than 20-30 grams of net carbohydrate per day if pursuing strict keto
Monitor with a glucose-ketone meter daily
Protect body weight — Involuntary weight loss erases any metabolic advantage. If weight drops, adjust the approach.
A modified Atkins diet or time-restricted eating window is a reasonable alternative if strict keto is unsustainable

Exercise

Research suggests that maintaining physical activity during cancer treatment may help preserve muscle mass, support immune function, reduce fatigue, and lower blood sugar. Many oncology guidelines suggest aiming for approximately 30 minutes of activity on most days, but patients must consult their physical therapy or oncology team to establish safe, individualized exercise thresholds during treatment. Fall risk, deep vein thrombosis, and fatigue levels vary significantly between patients.

Sleep and Circadian Rhythm

Sleep quality may be supported by a dark, cool sleeping environment, consistent sleep timing, limiting caffeine, and morning daylight exposure. Some published studies have explored the use of melatonin as a sleep and circadian adjunct in oncology patients; patients interested in melatonin supplementation should discuss appropriate timing and dosages with their oncologist.

Dietary Supplement Notice: Statements regarding dietary supplements (including boswellia, melatonin, and curcumin) have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Always inform your medical team of any supplements you are taking or considering, as they may interact with prescribed treatments.

Fatigue is one of the most common and underestimated parts of GBM treatment — it builds during radiation, peaks in the weeks afterward, and is compounded by chemotherapy, steroids, seizure medicines, and the emotional weight of the illness. It is not laziness or weakness, and managing it well protects both function and morale.

Plan around your energy, not against it. Most people have better and worse times of day — schedule important activities for the good windows and build in rest. Short rests are better than long daytime sleeps that disrupt night sleep.
Keep gently active. It is counterintuitive, but light activity (short walks, gentle movement) reduces fatigue better than complete rest, and helps preserve strength, mood, and sleep. Ask your team about safe limits, especially regarding fall and clot risk.
Protect sleep. Steroids in particular cause insomnia — taking the last dose earlier in the day (with your team’s guidance), a consistent schedule, a dark cool room, and morning daylight all help.
Accept and ask for help. Let others handle cooking, driving, errands, and appointments. Setting up a help system (a shared calendar, a coordinator friend, platforms like CaringBridge) early reduces both the practical load and the fatigue of managing everything yourself.
Tell your team about treatable contributors. Anemia, low thyroid, depression, poorly controlled seizures, and some medications all worsen fatigue and may be fixable. Sudden or severe new fatigue, or fatigue with confusion or weakness, should be reported promptly — it can signal something that needs attention.
Simplify decisions and routines. Cognitive fatigue is real; written checklists, a pill organizer, and a single notebook for questions and appointment notes lighten the daily mental load.

The goal during treatment is not to push through at full speed but to spend your available energy on what matters most to you — and to let the rest go without guilt.

Candidates Worth Discussing with Your Medical Team

Off-Label Drug Information: The medications discussed in this section have not been approved by the U.S. Food and Drug Administration (FDA) for glioblastoma. They are approved for other conditions and have been studied in GBM to varying degrees. Using a drug off-label is a decision between the patient and their prescribing physician. This site does not endorse off-label use, recommend specific suppliers, or guarantee safety or efficacy. All evidence levels cited are from specific studies and do not predict individual outcomes. Discuss all options, risks, and potential interactions with your neuro-oncologist before considering any addition to standard care.

A small number of existing medications have enough published evidence to merit a conversation with the treating oncologist. None should be started without the oncologist's specific approval. All are considered additions to standard care, never replacements.

The principle of careful addition. Add one agent at a time, with 2-4 weeks of monitoring between additions and regular lab work, so that any problems can be attributed to the right cause. Adding multiple agents simultaneously makes troubleshooting impossible.

An anti-parasite drug with anti-cancer activity in laboratory studies. A Phase 1 trial at Johns Hopkins enrolled 24 patients with high-grade glioma alongside standard temozolomide. Published survival numbers were encouraging compared to historical expectations. The specific formulation matters — standard over-the-counter versions may not achieve adequate blood levels. Discuss sourcing and dosing with the oncologist. Main monitoring concern: liver enzymes.

A London-based clinic has published retrospective data on a combination of metformin, atorvastatin, mebendazole, and doxycycline used alongside standard care. Each component is a medication approved for other indications. The published evidence in glioblastoma is observational and limited — no large randomized controlled trial has been completed for this combination in GBM. Discuss individual components, potential interactions, and monitoring requirements with your oncologist.

A small randomized trial reported a reduction in MRI-measured peritumoral edema with a standardized boswellia preparation (high AKBA content) in irradiated brain tumor patients compared to placebo. Whether this translates to clinical benefit, reduced steroid need, or improved outcomes for any individual patient is unknown. Boswellia is a dietary supplement, not an FDA-approved drug. Discuss with your oncologist before adding it, particularly regarding potential interactions with other medications.

Research from the Karolinska Institute and others has reported that a high percentage of GBMs show signs of cytomegalovirus inside tumor cells. Published data suggest a possible survival association with the antiviral drug valganciclovir in CMV-positive patients, but the evidence has been debated in the field and the results have not been replicated in larger randomized trials. There is no FDA-approved use of valganciclovir for glioblastoma. The cost of testing the tumor for CMV is modest, and if positive it opens a conversation about whether adding an antiviral is appropriate. Discuss with your medical team.

Knowing which drugs have been deliberately excluded is as important as knowing which are included. The following were considered and excluded based on specific evidence:

Disulfiram + copper — EXCLUDED: negative randomized trial. Disulfiram (Antabuse) combined with copper supplements showed impressive anticancer activity in laboratory studies, which generated significant excitement in GBM patient communities. However, the only completed randomized controlled trial of this combination in newly diagnosed GBM (Huang et al., JAMA Network Open March 2023; 88 patients) showed no survival benefit. More concerning: the disulfiram + copper group had more serious adverse events (34% grade 3+ events vs. 11% in the control group), and median overall survival numerically favored the control arm (8.2 months control vs. 5.5 months disulfiram + copper, not statistically significant but directionally negative). Liver toxicity is a real risk with disulfiram, and copper chelation can compound this. Lab results do not reliably predict clinical results in GBM. Disulfiram + copper is not included in this guide’s discussion of agents worth considering. See also the Emerging Research & Negative Results section for the full trial details.
Hydroxychloroquine (HCQ) — EXCLUDED pending better evidence; significant monitoring requirement if considered. Hydroxychloroquine targets autophagy (a cellular recycling pathway that some chemotherapy drugs partially depend on to induce cell death), which gives it theoretical appeal in GBM. Small early studies have shown some signal. However, the evidence base in GBM remains weak, and HCQ carries a well-characterized, cumulative retinal toxicity risk at therapeutic doses: bull’s-eye maculopathy, which affects color vision and peripheral vision, can become permanent even after discontinuing the drug. In patients with autoimmune conditions who take HCQ long-term, regular ophthalmology surveillance every 6 months is mandatory for this reason. Any GBM patient and physician who discuss adding HCQ must understand that this monitoring requirement applies — it is not optional. HCQ is not currently included in this guide’s discussion of agents worth discussing with your team based on available evidence.

If either of these agents is included in a protocol you are reading about online, ask your medical team directly about the Huang et al. 2023 trial result and the HCQ ophthalmology monitoring requirement before considering them.

St. John’s Wort — Strongly induces CYP3A4 liver enzymes, which significantly reduces blood levels of many drugs including temozolomide and other chemotherapy agents. Avoid entirely during treatment. This is not a theoretical concern — it is a documented pharmacokinetic interaction.
Unregulated cannabis oil marketed as a cancer cure — Cannabis may be useful for symptom management (nausea, appetite, sleep, pain — discuss with your team). However, unregulated products marketed online as cancer cures are not standardized for dose or purity, and the cancer-specific claims are not supported by evidence. Some CBD products can inhibit CYP2C19, which processes several medications commonly used in GBM care. Tell your team about any cannabis products you are using.
High-dose intravenous vitamin C — No good evidence of benefit in GBM. High-dose IV vitamin C can interact with several oncology agents and has caused adverse events in published case reports.
Stacking multiple herbal supplements simultaneously — Even individually safe supplements can be problematic in combination. Published case reports describe severe liver toxicity when multiple herbal supplements (often including boswellia, curcumin, and others) were taken simultaneously alongside chemotherapy. Keep the supplement list short, add one at a time, and ensure your entire medical team can see every supplement you are taking. Use the NaturaBridge herb-drug interaction tool at trouvera.org before adding anything new.
Shark cartilage, laetrile (amygdalin), and similar unproven cancer remedies — No credible evidence of benefit in any cancer, meaningful risk of harm and financial loss, and possible delays in seeking effective treatment.

Emerging Research & Negative Results

This section covers investigational approaches and trial results that patients and families may encounter online. Understanding what has been tested — including what has not worked — is essential for making informed decisions. None of the emerging approaches below are approved treatments for glioblastoma.

Perillyl alcohol is a naturally occurring monoterpene that has been studied as an intranasal delivery agent for recurrent malignant glioma. The largest published experience comes from Fluminense Federal University in Brazil, led by da Fonseca and colleagues.

Key data: A cohort of 198 patients with recurrent malignant glioma (including a subset of 89 with recurrent primary GBM) received inhaled perillyl alcohol four times daily. The results were published in Anticancer Research 2013 (PMID 24324108; see also PMC7879254). The published survival data were encouraging relative to historical expectations for recurrent disease.

Critical disambiguation. The Brazilian program used commercial-grade perillyl alcohol — this is not the same as “NEO100,” a separate US-based program using a highly purified cGMP-grade formulation. The NEO100 Phase I trial enrolled only 12 patients across 4 US centers. These are two distinct programs with different formulations, and results from one should not be attributed to the other.

Not approved anywhere. Intranasal perillyl alcohol is not approved by the FDA or any other regulatory body for the treatment of glioblastoma or any other cancer. It remains investigational. The published evidence is from a single-center, non-randomized study without a control group. Do not pursue this outside of a clinical trial without discussing it thoroughly with your neuro-oncologist.

Nabiximols (brand name Sativex) is a standardized oromucosal spray containing THC and CBD in a defined ratio. A Phase 1b randomized, placebo-controlled trial in recurrent GBM was published in the British Journal of Cancer 2021 (PMC8039032).

Key data: In Part 2 of the trial, 1-year survival was 83% (10 of 12 patients) in the nabiximols group compared to 44% (4 of 9 patients) in the placebo group (p=0.042). Two placebo patients died within the first 40 days.

Very small sample size — interpret with extreme caution. The key comparison involved only 12 treatment patients and 9 placebo patients. The trial was a Phase 1b study and was not powered for survival as a primary outcome — the primary endpoint was safety and dose-finding. With sample sizes this small, individual patient variation can dramatically change the percentages. Much larger trials would be needed to confirm or refute any survival benefit. Do not make treatment decisions based on this study alone. Discuss with your medical team.

Disulfiram (Antabuse), an alcohol-deterrent drug, showed anticancer activity in laboratory studies when combined with copper. This led to a Phase II/III randomized controlled trial in newly diagnosed GBM, published in JAMA Network Open in March 2023 (PMC10066460). The trial enrolled 88 patients.

Key results: No significant survival benefit was found. Six-month survival was 62% (disulfiram + copper) vs. 44% (control), but this difference was not statistically significant (p=0.10). Median overall survival actually favored the control arm: 8.2 months (control) vs. 5.5 months (disulfiram + copper). Patients in the disulfiram + copper group experienced more adverse events: grade 3 or higher adverse events occurred in 34% of the treatment group compared to 11% of the control group.

Do not use disulfiram + copper for GBM outside of a clinical trial. This is the only completed randomized trial of this combination in GBM, and it showed no benefit with increased toxicity. Despite ongoing interest in online patient communities, the trial evidence does not support its use. Laboratory results did not translate to clinical benefit. Discuss with your medical team before considering any off-label drug combination.

Tissue Banking and Growing the Tumor Outside the Body

Several powerful future options depend on having the patient's tumor tissue preserved correctly. The key question is not whether everything ideal was done at surgery — but rather what is preserved and what remains possible with it.

What Banked Tissue Can Enable

Dendritic cell vaccines — Made from the patient's own immune cells, trained to recognize the specific tumor. Research continues on multiple fronts.
Organoid drug screening — Growing tumor cells in laboratory dishes to test which drugs work against this specific tumor. Available at a small number of academic centers.
Expanded molecular testing — Additional testing can often be performed on stored tissue months or years later.

If a second surgery ever becomes necessary, explicitly request snap-freezing of fresh tissue at that time.

Liquid Biopsy and ctDNA Monitoring

Circulating tumor DNA (ctDNA) refers to fragments of DNA shed by tumor cells into body fluids — primarily blood plasma (“liquid biopsy”) or cerebrospinal fluid (CSF). In some cancers, ctDNA monitoring has become a routine tool for tracking treatment response, detecting recurrence early, and re-profiling tumors without repeat surgery. In GBM, the story is more complicated, and understanding the limits is important before interpreting any result.

The GBM-Specific Challenge

GBM sheds significantly less ctDNA into blood than most systemic cancers. There are two reasons. First, the blood-brain barrier and blood-tumor barrier restrict the passage of tumor cell fragments from the brain into systemic circulation. Second, GBM is anatomically distant from high-volume blood vessels in the way that metastatic lung or colorectal cancer is not. The practical result: blood-based ctDNA sensitivity for GBM is approximately 30–40% in published series — meaning roughly 60% of GBM patients with active disease will have a negative blood ctDNA result. This is in contrast to 70–90% sensitivity for colorectal, lung, or breast cancers, where liquid biopsy has become standard.

A negative blood ctDNA test in a GBM patient does not rule out active disease. This is the most important thing to understand before ordering or interpreting a liquid biopsy.

CSF ctDNA: More Sensitive, More Invasive

Cerebrospinal fluid samples the central nervous system directly and bypasses the blood-brain barrier problem. Published studies have shown CSF ctDNA is substantially more sensitive than blood-based ctDNA for detecting GBM — some series report detection rates of 60–80% or higher, though this varies by tumor location (proximity to CSF spaces) and disease burden. The tradeoff: CSF requires a lumbar puncture (spinal tap), an invasive procedure with a small but real risk of headache, infection, and neurological complications that must be weighed against the clinical benefit of the information.

CSF ctDNA is not currently a routine procedure in GBM care. It is most likely to provide actionable information at the time of confirmed or suspected recurrence, particularly when re-biopsy by surgery carries unacceptable risk.

Guardant360 and Other Commercial Platforms

Guardant360 (Guardant Health) is an FDA-authorized blood-based ctDNA assay used for multiple solid tumor types. It can detect GBM in a subset of patients but, as noted, the sensitivity is meaningfully lower for GBM than for systemic cancers. Guardant360 and similar platforms (Foundation Medicine cfDNA, Tempus xF) are most useful when they return a positive result — a detected mutation can guide therapy or confirm molecular features. A negative result in GBM must be interpreted cautiously.

When Liquid Biopsy Is Clinically Useful in GBM

First sign of MRI change — pseudoprogression vs. true recurrence. When an MRI shows new or enlarging enhancement within the first 3–6 months after chemoradiation, the differential includes true tumor progression and pseudoprogression (radiation-induced inflammation that mimics tumor growth, occurring in ~25% of patients). A blood ctDNA result — if positive and showing tumor-specific mutations — supports true progression. If negative, it does not exclude progression (given the sensitivity limits) but may add one more piece of data alongside perfusion MRI, amino-acid PET, and short-interval repeat imaging. Used together, these tools improve confidence without exposing the patient to premature treatment change based on a single MRI.
Repeat molecular profiling at recurrence when surgery is not feasible. GBM evolves under treatment pressure. New mutations can emerge that open access to targeted therapies or trials. If a patient has a focal recurrence that is not safely resectable, CSF ctDNA (via lumbar puncture) can provide molecular re-profiling data that would otherwise require tissue. This is one of the most promising clinical applications of liquid biopsy in GBM.
Monitoring treatment response over time. Serial ctDNA measurements — the trend over multiple blood draws — may be more informative than a single result. A rising ctDNA signal after initiating a new treatment would suggest lack of response; a declining or stably undetectable signal would suggest tumor control. Research protocols are exploring this application, but it is not yet standardized practice.
Identifying acquired resistance mechanisms. If the tumor recurs after temozolomide, ctDNA profiling may reveal new mutations (such as acquired MGMT unmethylation or new oncogenic drivers) that explain the resistance and suggest next-line approaches.

The Future of ctDNA in GBM

ctDNA and cell-free DNA (cfDNA) monitoring in brain tumors is an active research area, and sensitivity will likely improve as panels are refined and CSF protocols become more standardized. Several academic centers and commercial laboratories are running prospective studies. Ask your neuro-oncologist whether liquid biopsy — blood or CSF — is appropriate for your specific clinical situation, particularly at first sign of MRI change or confirmed recurrence.

Bottom line: Liquid biopsy is a useful but imperfect tool in GBM, limited by the blood-brain barrier. A positive result is informative; a negative blood result does not rule out active disease. CSF ctDNA is more sensitive but invasive. Discuss with your team at what clinical juncture it would add actionable information to your specific situation.

The Molecular Decision Tree

Once molecular results return, the treatment plan branches. This is one of the most important decision points in the entire process.

Most Common Scenarios

These tumors respond significantly better to temozolomide. One important discussion is whether to use the investigational CeTeG regimen (adding lomustine). The NOA-09 trial (141 randomized, 129 treated) showed a survival difference of roughly 16–17 additional months in the trial population, but CeTeG remains investigational — it has not yet changed standard-of-care guidelines and involves increased toxicity. For an MGMT-methylated patient with good performance status, discuss with your neuro-oncologist whether the potential benefit outweighs the additional side effects.

Standard temozolomide is less effective. Clinical trial enrollment becomes a higher priority. A key trial to ask about is Gliofocus (niraparib, a PARP inhibitor; NCT06388733), which is enrolling MGMT-unmethylated patients. Ask your care team which open trials fit your tumor's molecular profile.

This technically changes the diagnosis to a different disease (astrocytoma, IDH-mutant, grade 4). The prognosis is generally better, and the treatment menu shifts. Vorasidenib (Voranigo) is FDA-approved for grade 2 IDH-mutant astrocytoma and oligodendroglioma only — not for grade 4. Trials in higher-grade IDH-mutant disease are ongoing. Eligibility for off-label use should be discussed with the medical team.

BRAF V600E: Opens dabrafenib + trametinib (FDA-approved across solid tumors). The FDA granted Breakthrough Therapy Designation to plixorafenib (Fore Biotherapeutics) on April 1, 2026 for BRAF V600E-mutated high-grade glioma based on early-phase data in BRAF V600 primary CNS tumors. Plixorafenib is not yet FDA-approved; the ongoing Phase 2 FORTE basket study (NCT05503797) is the main current avenue for access.
NTRK fusion: Opens larotrectinib or entrectinib (tumor-agnostic FDA approval)
H3 K27M: Opens dordaviprone (Modeyso, FDA accelerated approval 2025 for recurrent/progressive disease after prior therapy)
MTAP deletion: Opens the MRTX1719 clinical trial
Hypermutated tumor: Makes immune checkpoint inhibitors more reasonable

class="content-section" data-stage="treatment,recurrence">

Clinical Trials: A Treatment Option, Not a Last Resort

Trial Information Changes Frequently: Eligibility criteria, enrollment status, and available sites for clinical trials change on a weekly basis. The trials listed here were actively enrolling as of May 2026. Always verify current status on ClinicalTrials.gov or directly with the treating center before making plans. Participation in any trial is between the patient and the research team; this guide does not recommend or endorse specific trials.

Clinical trials should be considered alongside standard care, not only when other options fail. The Stupp protocol itself was once a trial. Every effective GBM treatment today started as a trial.

Key Trials to Ask About (2026)

Gliofocus (NCT06388733) — Phase 3 trial of niraparib vs. temozolomide in MGMT-unmethylated GBM. Study drug provided free. One of the highest-value trial considerations for unmethylated patients.
GBM AGILE (NCT03970447) — Platform trial testing multiple experimental treatments simultaneously. Available at many centers.
EF-41 / KEYNOTE D58 (NCT06556563) — Tests Optune + temozolomide + pembrolizumab. Entered after chemoradiation.
DIET2TREAT (NCT05708352) — Randomized trial of ketogenic diet plus standard care.
SONOBIRD (NCT05902169) — Phase 3 trial of SonoCloud-9 (BBB-opening) + carboplatin vs. standard chemotherapy (lomustine or temozolomide) in recurrent GBM.

How to Search for Trials

Visit ClinicalTrials.gov, search for "glioblastoma," filter by "recruiting" status and location. Your cancer center's clinical trials office can also help identify eligible trials.

Not every trial is a good fit, and the listings can be overwhelming. A few practical questions help you and your team evaluate any specific trial:

What phase is it, and what is the goal? Early-phase (Phase 1) trials primarily test safety and dose; later-phase (Phase 2/3) trials test whether a treatment actually works. Both can be worthwhile, but the expected benefit and purpose differ — ask which this is.
Do I actually qualify? Trials have strict eligibility criteria (tumor molecular features, prior treatments, performance status, organ function). Many people screen out, so confirm eligibility early rather than building hopes around one trial.
Is there a placebo or control arm, and could I receive standard care? Most GBM trials add an experimental treatment to standard care or compare against it — you should not have to forgo proven treatment. Clarify exactly what each arm receives and whether randomization is involved.
What is the burden? Extra scans, biopsies, clinic visits, or travel to a distant center all have real costs in time and energy. Ask what participation actually requires week to week, and whether travel or lodging help is available.
What does it mean for timing? Some trials require enrollment before standard treatment starts, which is why trial screening should begin early — even in the weeks right after surgery — not only after other options run out.
Can I leave if I want to? Yes — participation is always voluntary and you can withdraw at any time. Ask what follow-up looks like if you do.

Bring a specific trial’s identifier (its NCT number) to your neuro-oncologist and ask directly: “Do I qualify, is it available near me, and is it a better option for me than what we’re doing now?” The navigators listed below can also help you find and vet trials.

Patient Navigation Services

National Brain Tumor Society — Patient navigator: 800-934-2873
American Brain Tumor Association — CareLine: 800-886-2282
Musella Foundation — virtualtrials.org: 888-295-4740

Pregnancy and Glioblastoma

Glioblastoma during pregnancy is rare, but it does happen. It needs a coordinated team — neuro-oncology, neurosurgery, radiation oncology, and maternal-fetal medicine — because several standard treatments can harm a developing baby. The right plan depends on how far along the pregnancy is, how aggressive the tumor is, and the mother's symptoms. There is no single correct answer; decisions are made together with the family.

Key safety points

Temozolomide is not safe in pregnancy. It can cause serious birth defects and is normally avoided, especially in the first trimester. Anyone who could become pregnant should use reliable contraception during treatment. Men taking temozolomide are advised to use condoms and avoid fathering a child during treatment and for about 3 months after the last dose.
Radiation to the head can sometimes be given during pregnancy with careful shielding and dose planning, but the timing and the dose reaching the baby must be reviewed by the radiation team first.
Some anti-seizure medicines — particularly valproic acid (Depakote) — carry their own risk of birth defects. Tell your team if you are pregnant or could become pregnant so a safer seizure medicine can be chosen.
Tell your whole team early. If you are pregnant, think you might be, or are planning a pregnancy, say so before any scan, medicine, or radiation is started.

Questions to Ask Your Doctor

How does my pregnancy change the treatment you would normally recommend?
Which treatments can safely wait until after delivery, and which cannot?
What contraception should I use during and after chemotherapy?
Is my current seizure medicine safe in pregnancy, or should we switch?

If the Tumor Returns

Most GBM patients eventually experience recurrence. The treatments available at recurrence differ from initial treatment. Doing the thinking now — while the patient is still doing well — saves critical weeks when fast decisions matter.

Write this plan by Month 3 of initial treatment — while you are doing well. The recurrence playbook is not a plan to give up. It is the opposite: having your options researched and logistics pre-arranged so that if recurrence is confirmed, you can act in days rather than starting from scratch in a state of crisis. Families who have this plan in place describe a meaningfully different experience when recurrence happens — less panic, faster action, better decisions.

Your Recurrence Playbook Template

By Month 3, document answers to these questions. Keep this document somewhere both you and your medical advocate can immediately access — a phone note, a cloud folder, a printed page in the medication binder.

Which major center would we contact first? Write down the name, the phone number, and a contact person (navigator, trial coordinator, or nurse) if you have already established one. Centers to consider: Huntsman Cancer Institute (801-585-7800), MD Anderson (877-632-6789), UCSF (415-353-2966), Duke Tisch (919-684-5301), Northwestern (LITT, BBB-opening; 312-695-4360), Washington University St. Louis (LITT; 314-362-7172).
Have we contacted Ivy Brain Tumor Center? Y/N. If yes — what was their assessment of Phase 0 trial eligibility? Contact: 602-406-8605.
Which trials have we pre-screened for recurrence? List by name and NCT number. Note whether each requires specific molecular features we may or may not have. (GBM AGILE NCT03970447 is a platform trial with multiple recurrence arms; note current enrollment status.)
Does the tumor have CAR-T-relevant surface markers? From the molecular panel: Does the tumor express B7-H3, IL13Rα2, EGFRvIII, or HER2? If yes, note which markers and which centers are running CAR-T trials for that target (Stanford B7-H3, City of Hope IL13Rα2, Penn EGFRvIII, MGH GD2).
Have we pre-contacted an international center? Y/N — if yes, which center, what eligibility information was discussed, and what is the estimated cost and logistics?
What is the plan for molecular re-profiling at recurrence? If surgery is possible, will we request full NGS repeat? If surgery is not feasible, will we pursue CSF ctDNA? Who will order it?
Has the advance directive been reviewed since diagnosis? Has anything changed about what the patient wants in extreme circumstances? Is the healthcare proxy aware and prepared?
What does the patient most want to protect if options narrow? This is a goals-of-care question to discuss with the palliative care team. Write down: what matters most (function, communication, staying home, being present for a specific event). This guides the whole team when difficult decisions arise.

Living with the knowledge that GBM usually returns is one of the hardest parts of the disease. Preparing for it — while you are well — is not pessimism; it is what lets you act quickly and on your own terms if it happens, and it can reduce the background dread of the unknown.

Practical preparation (do while stable):

Build the recurrence “playbook” in advance. Identify which major brain-tumor centers and trials you’d want to consider, and make initial contact now so logistics aren’t starting from zero under time pressure.
Keep records organized and accessible — imaging, operative and pathology reports, molecular results, and treatment history — ideally in one place a family member can also reach.
Ask about re-testing the tumor if there’s a future surgery: the tumor changes over time, so fresh molecular profiling at recurrence can open new trial options.
Confirm your wishes are documented (advance directive, healthcare proxy) while everything is clear — this is a gift to your family, not a sign of giving up.

Emotional preparation:

Scan anxiety is real and common. The days around surveillance MRIs (“scanxiety”) are hard for almost everyone. Naming it, leaning on support, and planning something grounding around scan days can help.
You do not have to hold it alone. A counselor experienced with serious illness, a support group, or a brain-tumor community (National Brain Tumor Society, American Brain Tumor Association) can carry some of the weight.
Living well between scans is part of treatment. Preparing for recurrence does not mean living in its shadow — many people find that having a plan frees them to focus on the good days in between.

If recurrence is confirmed, the steps below outline how decisions are approached. Having read them in advance means you’ll recognize the path rather than facing it cold.

Step 1: Confirm True Progression vs. Pseudoprogression

About 25% of patients show imaging changes after radiation that mimic tumor growth but are actually treatment-related inflammation. The medical team distinguishes these using perfusion MRI, amino-acid PET scanning, MR spectroscopy, or short-interval repeat imaging. Do not let an early suspicious scan trigger premature treatment changes.

Step 2: Repeat Molecular Testing

The tumor evolves under treatment pressure. If surgery is performed for recurrence, the new tissue should undergo full molecular profiling again — including surface markers for CAR-T eligibility.

Step 3: Salvage Pathway Options (Discuss with Medical Team)

Repeat surgery with GammaTile — If the recurrence is focal and surgically accessible. GammaTile (Cs-131 brachytherapy) is available mainly at centers with neurosurgeons experienced in brachytherapy; not all centers offer it.
LITT combined with immunotherapy — Early-phase studies have shown encouraging results for focal recurrence, but this combination remains investigational with limited data
Re-irradiation — Feasible for many recurrences, especially with longer intervals from initial radiation
BBB-opening drug delivery — Focused ultrasound trials at centers including Northwestern and University of Maryland
Targeted molecular trials — Matched to the tumor's specific mutations
CAR-T cell therapy — There is no approved CAR-T therapy for GBM; all options are early-phase clinical trials at major centers, requiring specific antigen expression on the tumor (B7-H3, IL13Rα2, EGFRvIII, or HER2)
Oncolytic virus therapy — Including G47Δ (approved in Japan) and other investigational approaches
Bevacizumab — Does not extend overall survival but can rapidly improve quality of life by controlling swelling
International options — BNCT in Japan, NanoTherm in Germany (see International Options)

Decision Triggers — When to Act

New MRI shows possible recurrence: Request imaging copy and full radiology report. Ask the medical team within 48 hours for their interpretation.
Tumor confirmed as recurrent: Request expanded molecular testing. Contact pre-identified trial centers.
New seizures, weakness, speech changes, or confusion: Contact medical team within 24 hours.
Sudden shortness of breath or chest pain: Possible pulmonary embolism. Call 911.
Fever during chemotherapy: Neutropenic fever can be life-threatening. Contact the team same day.

Major Brain Tumor Centers by Region

No endorsement or affiliation. Listing here does not constitute a recommendation or endorsement of any specific center, physician, or program. Trouvera has no financial relationship with any center listed. Specialties and trial participation noted are based on publicly available information as of May 2026 and may change. Verify all information directly with the center when contacting them.

The difference between a strong academic cancer center and a general community hospital can be significant for GBM. These centers have dedicated multidisciplinary brain tumor teams. Contact information is provided for new-patient inquiries — verify when calling, as details can change.

UCSF Brain Tumor Center

San Francisco, CA

Comprehensive neuro-oncology program, active trial portfolio

Neuro-Oncology: 415-353-2966 • Neurosurgery: 415-353-7500

Stanford Health Care

Stanford, CA

B7-H3 CAR-T cell therapy program

Phone: 650-498-6000

City of Hope

Duarte, CA

IL13Rα2 CAR-T cell therapy program

Brain Tumor Program: 626-218-6555

UCLA Brain Tumor Center

Los Angeles, CA

Dendritic cell vaccine research

Phone: 310-825-5111

Huntsman Cancer Institute

Salt Lake City, UT

NCI Comprehensive Cancer Center for the Mountain West. Proton therapy, GBM AGILE site, advanced surgical techniques.

Phone: 801-587-7000

Mayo Clinic — Phoenix

Phoenix, AZ

Active brain tumor program, clinical trials

Phone: 480-301-8000

Ivy Brain Tumor Center at Barrow Neurological Institute

Phoenix, AZ

Largest Phase 0 brain tumor trial program in the world. Sponsor of the Gliofocus trial.

Navigator: 602-406-8605 • Trial Screening: 602-406-6489

MD Anderson Cancer Center

Houston, TX

Major brain and spine center with extensive trial portfolio

New Patient: 877-632-6789 • Direct: 713-792-6600

Northwestern Memorial Hospital

Chicago, IL

Active SonoCloud-9 site for focused ultrasound BBB-opening trials

Lou & Jean Malnati Brain Tumor Institute: 312-695-4360

Washington University in St. Louis

St. Louis, MO

Major LITT center. Published landmark LITT + immunotherapy data.

Neurosurgery: 314-362-7172

Cleveland Clinic

Cleveland, OH

Rose Ella Burkhardt Brain Tumor Center. LITT and integrated brain tumor program.

Phone: 866-588-2264

Mayo Clinic — Rochester

Rochester, MN

Active brain tumor program across all three campuses

Phone: 507-538-3270

Henry Ford Hermelin Brain Tumor Center

Detroit, MI

Active brain tumor program with clinical trial participation

Phone: 888-777-4167

Duke Preston Robert Tisch Brain Tumor Center

Durham, NC

Pioneering immunotherapy and oncolytic virus research. Active LITT center.

Phone: 919-684-5301 • Screening: 866-385-3123

University of Florida Health

Gainesville, FL

LITT program, KEYNOTE D58 trial site

Phone: 352-265-1000

Mayo Clinic — Jacksonville

Jacksonville, FL

Active brain tumor program

Phone: 904-953-0853

Dana-Farber / Brigham Cancer Center

Boston, MA

Center for Neuro-Oncology. Major research and trial program.

Phone: 877-442-3324

Massachusetts General Hospital

Boston, MA

CAR-T cell therapy and immunotherapy research

Brain Tumor: 617-724-8770

Memorial Sloan Kettering Cancer Center

New York, NY

Comprehensive brain tumor center

New Patient: 800-525-2225

Weill Cornell Medicine

New York, NY

GBM organoid drug screening program

Brain & Spine: 212-746-4684

University of Pennsylvania

Philadelphia, PA

EGFRvIII CAR-T cell therapy program

Phone: 215-829-6700

University of Pittsburgh Medical Center

Pittsburgh, PA

Major LITT center

Phone: 412-647-3685

International Options

Several international centers offer treatments not yet approved in the United States. These are generally best held as recurrence contingencies — pre-planned while the patient is stable but executed when standard domestic options need escalation.

Important note on international treatments. G47Δ (Delytact), BNCT, and NanoTherm are not FDA-approved in the United States. They are regulated and approved under different frameworks in their home countries (Japan and the European Union). The standards used by foreign regulatory authorities differ from those of the FDA. Outcomes data from these centers come primarily from single-arm studies rather than randomized comparisons against U.S. standard of care. International medical travel during serious illness carries significant clinical, financial, and logistical risks. Discuss any international option with your U.S. medical team before committing, and obtain current written cost estimates and clinical eligibility confirmations directly from the international center.

Practical framing. International trips during the most aggressive disease window carry real costs in time, energy, and money. Pre-contact international centers early, hold them as contingencies, and use them when the timing fits. Avoid traveling overseas on hope alone when better-evidenced options remain available closer to home.

Japan: Boron Neutron Capture Therapy (BNCT)

BNCT is a precision radiation approach built on a two-step mechanism. First, a boron-containing compound (typically boronophenylalanine, BPA) is infused intravenously. Tumor cells take up the BPA preferentially over normal cells because they have higher metabolic activity. A beam of low-energy neutrons is then directed at the tumor. When a neutron collides with a boron-10 atom inside a tumor cell, a nuclear reaction occurs that releases two short-range, high-energy particles — an alpha particle and a lithium ion — that kill the cell from within, while sparing adjacent normal cells that absorbed little boron. The effective range of the reaction is approximately one cell diameter, making the cell-killing highly localized.

BNCT using accelerator-based neutron sources (more practical than reactor-based systems) was approved in Japan in 2020 for recurrent unresectable head and neck cancer and for recurrent glioma. The Osaka International Cancer Institute operates an active BNCT program using an accelerator-based system. The Southern Tohoku BNCT Research Center in Fukushima and the Kansai BNCT Medical Center at Osaka Medical and Pharmaceutical University are additional Japanese sites.

Published Phase 2 data from Japan for recurrent glioma (including recurrent GBM) have reported median overall survival of approximately 10–11 months from the time of BNCT treatment in selected patients, though patient selection factors — typically younger age, better performance status, prior standard therapy — make direct comparison with other salvage approaches difficult. These are encouraging numbers for recurrent disease, though not definitive.

Access logistics: BNCT in Japan is not available to US patients through insurance. Treatment requires a multi-week stay in Japan (initial evaluation, treatment planning, neutron beam treatment over approximately 1–2 sessions, and follow-up). Costs include treatment fees, travel, accommodation, and medical translation services. Pre-contact these centers while stable during Phase 2 of initial treatment to understand the eligibility criteria and logistics rather than exploring this for the first time at recurrence under time pressure.

BNCT is not available in the United States as of mid-2026. TAE Life Sciences is pursuing NovaBay-based accelerator BNCT development for a US program; the regulatory pathway is underway but no approved US center exists yet.

Germany: Interdisciplinary Molecular Tumor Board (iMDT) Access

Germany operates a network of Comprehensive Cancer Centers (CCCs) certified by the German Cancer Aid (Deutsche Krebshilfe), of which the NCT Cancer Center at Heidelberg is among the most prominent for CNS tumors. These centers run interdisciplinary molecular tumor boards (iMDTs) where neuro-oncologists, neuropathologists, radiation oncologists, molecular biologists, and neurosurgeons jointly review complex cases.

For GBM patients with unusual molecular findings — rare mutations (BRAF V600E, NTRK fusions, H3 K27M), hypermutated tumors (TMB-high), or tumors with multiple potentially targetable alterations — a second opinion from a center like Heidelberg’s NCT can identify European trial options or targeted therapy combinations not available in the US. Some of these consultations can be conducted remotely (digital pathology, imaging upload, teleconference).

NanoTherm magnetic hyperthermia (MagForce AG) — CE-marked in the EU for recurrent GBM — is mentioned elsewhere in this guide. It is administered at centers in Berlin and Warsaw. Clinical experience remains limited (mostly single-arm studies); it is best understood as an option for select recurrent GBM patients who have exhausted other local therapies.

Practical note: Unlike BNCT, which is a self-contained treatment course, pursuing ongoing care in Germany from the US creates significant continuity-of-care challenges. German centers are most appropriately used for second opinions, specific procedure access (NanoTherm, if eligible), or trial enrollment — not as a primary care anchor while living in the US.

Practical Guidance for International Treatment Decisions

International treatment carries real risks during active GBM management. The continuity of care that GBM requires — emergency management of new seizures or sudden neurological deterioration, steroid dose adjustment, MRI interpretation, blood count monitoring during chemotherapy — depends on a team that knows the patient’s history and can respond immediately. Interrupting that relationship for international travel during the most medically complex period creates meaningful risk.

International treatment is most appropriate in two scenarios: (1) a self-contained procedure (BNCT, one course of treatment) after which care returns to the home team, or (2) a second opinion consultation that informs the US care team without replacing it. The worst scenario is fragmented ongoing care split between a US oncologist and an international center with poor communication between them.

Pre-contact international centers early — during Phase 2 of initial treatment — not at the moment of recurrence. Understand their eligibility requirements, get written cost estimates, and discuss the logistics with your US medical team so everyone is aligned before a crisis occurs. Holding international options as contingencies costs nothing; trying to organize them under recurrence pressure can cost critical weeks.

A triple-mutated herpes virus engineered to replicate inside cancer cells and stimulate an immune response. Conditionally approved in Japan since 2021 for malignant glioma — the first approved oncolytic virus for brain cancer anywhere in the world. Delivered by injection into residual or recurrent tumor at the University of Tokyo. Treatment requires a multi-week stay in Japan.

A precision radiation therapy where a boron-containing drug is taken up by tumor cells, then the area is irradiated with neutrons triggering a nuclear reaction that kills tumor cells with minimal damage to surrounding tissue. Available at centers in Osaka and Fukushima. Published data show encouraging survival numbers in recurrent glioma.

Magnetic iron oxide nanoparticles injected into the tumor generate heat when exposed to an external alternating magnetic field, directly damaging tumor cells. CE-marked in the European Union for recurrent GBM. Treatment at the MagForce center in Berlin.

Goals of Care: Palliative Care Alongside Active Treatment

Palliative care is among the most misunderstood concepts in oncology. The name suggests end-of-life, which causes many patients and families to reject it precisely when they need it most. This section explains what palliative care actually is, what it provides in GBM specifically, and when to engage it (the answer is: from the beginning, not at the end).

What Palliative Care Is — and What It Is Not

Palliative care is not hospice. Hospice is a specific Medicare benefit for patients who have elected to focus exclusively on comfort and have a prognosis of six months or less. Palliative care is entirely different: it is a medical specialty focused on symptom management, quality of life, and communication support that runs alongside curative or life-extending treatment from the very beginning of a serious illness. A patient actively pursuing every available GBM treatment — surgery, chemoradiation, Optune, clinical trials — can and should also have palliative care support in parallel.

The evidence for this is striking. A landmark 2010 NEJM trial by Temel and colleagues in metastatic lung cancer (a disease with a similarly poor prognosis to GBM) showed that patients who received early palliative care alongside standard oncology treatment had better quality of life, less depression, fewer aggressive interventions at the end of life, and — unexpectedly — longer median survival (11.6 vs. 8.9 months). The mechanism appears to involve better symptom control allowing patients to continue treatment longer, and avoidance of medically futile late-stage ICU admissions. While this trial was in lung cancer, not GBM, the principles are directly applicable and neuro-oncologists increasingly refer patients early.

What Palliative Care Provides for GBM Patients Specifically

Headache and pain management — Brain tumor headaches (often worst in the morning, associated with nausea) require a management strategy beyond over-the-counter pain relievers. Palliative care specialists have experience with the interactions between tumor medications, steroids, and pain management.
Nausea, appetite, and weight management — Chemoradiation nausea, steroid-induced appetite changes, and treatment-related weight loss all respond to targeted interventions that a palliative care team is expert in.
Fatigue management — Treatment-related fatigue in GBM is multifactorial (tumor, radiation, chemotherapy, steroids, anti-seizure medications, sleep disturbance). Palliative care can identify which components are most modifiable and prioritize accordingly.
Seizure-related anxiety — The unpredictability of seizures causes significant anxiety in patients and families. Palliative care provides psychological support and practical planning strategies (driving restrictions, fall precautions, what to do during a seizure).
Sleep management — Dexamethasone commonly causes insomnia. Palliative care offers a structured approach to sleep: timing the steroid dose earlier in the day, sleep hygiene, and when appropriate, medication.
Communication support — Helping patients and families have the conversations that matter — with each other, with the medical team, and about what lies ahead — is a core palliative care skill. This includes translating complex treatment options into practical decision frameworks and facilitating family meetings when needed.
Goals-of-care clarification — Not just “do you want CPR?” but a deeper conversation: What does quality of life mean to you? What functions or abilities are non-negotiable? What would make you consider changing your treatment goals? These answers guide every subsequent decision, and they are best explored while the patient is cognitively intact and not in crisis.

When to Engage Palliative Care

From diagnosis — not at end of life. Ask your neuro-oncologist at the first appointment: “Can I meet with the palliative care team?” At Huntsman Cancer Institute, the Supportive Oncology and Survivorship (SOS) program provides palliative care alongside active oncology treatment. Call 801-587-7000 and ask for the Supportive Oncology and Survivorship program. At other centers, ask your oncology team to place a palliative care referral.

Cognitive Symptoms: A Separate Specialist Layer

Because glioblastoma and its treatments directly affect brain function, cognitive symptoms require a specialized assessment beyond what general palliative care provides. These resources are worth requesting early:

Neuropsychological testing. A formal evaluation by a neuropsychologist establishes a cognitive baseline early in treatment and can identify subtle deficits — in memory, processing speed, executive function, or word-finding — before they significantly affect daily life. Repeat testing can track changes and guide rehabilitation. Ask your neuro-oncologist for a referral to a neuro-psychologist.
Occupational therapy for cognitive rehabilitation. Occupational therapists with oncology experience provide practical strategies for cognitive challenges: memory aids, routine structuring, task simplification, and home safety assessment. They can also evaluate activities of daily living that may be affected by tumor location or treatment.
Driving evaluation. Brain tumor, seizures, and cognitive changes directly affect driving safety. In Utah, physicians are required to report seizures to the Driver License Division; patients who have had a seizure may not drive until a seizure-free period is established (typically 3–12 months depending on circumstances). Even without seizures, tumor location, medication effects, and fatigue may affect driving ability. A formal driving evaluation by an occupational therapist certified in driver rehabilitation is the safest way to determine whether driving remains safe. Do not assume driving is safe without this assessment if there is any cognitive or neurological change.
Speech therapy. For patients with word-finding difficulty, expressive aphasia, or communication challenges from tumor location or surgery, speech-language pathologists provide targeted rehabilitation. Early engagement preserves function better than waiting until deficits are severe.

The Advance Directive as a Living Document

An advance directive completed in Week 2–3 (as recommended in the First Seven Days Checklist) is the starting point, not a permanent document. The right question to ask at each major milestone — completing chemoradiation, at first surveillance scan, at recurrence — is: “Given where we are now, does the advance directive still reflect what I want?” Circumstances and values evolve. Review it with your healthcare proxy and medical team as the situation changes.

The practical question to ask at every major appointment: “If my disease progressed significantly tomorrow, what would we do? What would I want to do?” Asking this question while stable, rather than confronting it for the first time in crisis, is one of the most protective things a patient and family can do.

Supporting the Patient and Family

Caregiver Support

Designate more than one caregiver — rotation prevents burnout
Set up help early using platforms like CaringBridge or Lotsa Helping Hands
Family Caregiver Alliance: 800-445-8106
Most cancer centers offer caregiver support groups

Caregivers of someone with GBM carry one of the heaviest loads in all of cancer care, in part because the disease affects the brain — so cognition, communication, and personality may change, and the patient may not always be able to advocate for themselves. A few focused roles make the biggest difference, and sharing them across more than one person prevents collapse.

Be the medical advocate and record-keeper. Keep one organized place for imaging, reports, the medication list, and questions. Attend appointments, take notes, and ask the team to summarize the plan — two sets of ears catch far more, especially when the patient is fatigued or cognitively affected.
Watch for the changes that need a call. New or worsening weakness, speech trouble, confusion, or seizures; signs of a blood clot (one-sided leg swelling, sudden breathlessness, chest pain); fever during chemotherapy; or steroid problems (very high blood sugar, severe mood change). Knowing these turns vague worry into clear action.
Manage the medication and steroid schedule carefully. Steroids and seizure medicines must not be stopped or changed abruptly. A pill organizer and a simple log prevent dangerous errors.
Accept and organize help. Let friends and family take concrete tasks — meals, driving, childcare, errands — coordinated through a shared calendar or a single “captain.” Saying yes to help is not weakness; it is what makes caregiving sustainable.
Protect your own health. Caregiver burnout is real and well-documented in GBM. Sleep, breaks, your own medical care, and support (a counselor, a caregiver group, respite care) are not optional extras — the patient depends on you staying well.
Don’t take symptoms personally. Irritability, apathy, or lack of insight are usually the tumor or the treatment, not the person rejecting you. Naming it as a symptom protects the relationship.

You do not have to do this perfectly or alone. Building a small team early, and leaning on the support organizations and financial and travel resources listed in this guide, lightens a genuinely heavy job.

If Children Are Involved

Children need age-appropriate information. Trying to shield them entirely usually backfires. The American Cancer Society and CancerCare (800-813-4673) have resources specifically for helping families talk through these conversations.

Cognitive, Personality, and Emotional Changes

Because glioblastoma and its treatments affect the brain itself, changes in thinking, memory, mood, and even personality are common — and they are among the hardest parts of the illness for families, often more than the physical symptoms. Understanding that these are part of the disease, not a choice or a character change, helps everyone cope.

What can happen: Depending on where the tumor is, people may experience memory and concentration problems, slowed thinking or word-finding difficulty, fatigue, mood swings, irritability or apathy, and sometimes changes in judgment or personality. Treatment contributes too — radiation can cause delayed cognitive effects, steroids commonly cause mood changes and insomnia, seizure medicines can affect mood, and fatigue affects everything.
It is not the person choosing to be difficult. When a loved one becomes uncharacteristically irritable, withdrawn, or unaware of their deficits, that is the tumor or the treatment speaking. Taking it personally is understandable but adds suffering on both sides; naming it as a symptom helps.
Some causes are reversible. Confusion or decline can come from treatable things — steroid effects, seizures (including subtle non-convulsive ones), infection, blood clots, medication side effects, sleep loss, or depression — so a new or sudden change is worth reporting to the team rather than assuming it is the tumor progressing.
What helps: Neuropsychology assessment and rehabilitation (cognitive, speech, occupational therapy) can build coping strategies; simplifying the medication list and minimizing steroids where possible reduces the burden; routines, written reminders, and a calm environment ease daily life; and treating depression and anxiety (common and real) genuinely improves function and quality of life.
For caregivers: These changes can mean grieving the person’s former self while they are still here — an experience sometimes called anticipatory or ambiguous grief. It is valid, it is exhausting, and support (counseling, caregiver groups, respite) is not a luxury.

Mental Health

Anxiety, depression, and existential distress are very common — they are part of what this disease does, not signs of weakness
Seek a therapist experienced with cancer or chronic illness
Medication options exist if mood symptoms develop
Mindfulness-based stress reduction and faith community support are both valuable

Legal and Practical Documents

Complete these in the first two to three weeks after diagnosis while cognition is fully intact:

Will (create or review)
Durable power of attorney for finances
Durable power of attorney for healthcare
Advance directive
Beneficiary designations on financial accounts
Digital asset access for a trusted person

Financial Resources

Patient Advocate Foundation: 800-532-5274
CancerCare: 800-813-4673 (financial assistance grants)
Musella Foundation: 888-295-4740 (brain tumor-specific assistance)
Social Security Disability (SSDI): GBM qualifies for Compassionate Allowance fast-track. Apply at 800-772-1213.
Optune (Novocure) patient services for insurance authorization: 1-855-281-9301

Travel Assistance for Treatment

Mercy Medical Angels: 757-318-9145
Air Charity Network: 877-621-7177
Corporate Angel Network: 914-328-1313
American Cancer Society Hope Lodge: 800-227-2345

Early Detection & Family Risk: An Honest Assessment

Families often ask: “Could we have caught this earlier?” and “Are my children at risk?” The honest answers are important even when they are not the ones people hope for.

The short answer: not with current tools, for most people. Unlike the other diseases covered by Trouvera, glioblastoma has no reliable early detection test and no proven screening strategy for the general population. There is no blood test, no genetic screen, and no imaging study recommended for routine use in people without symptoms.

This is fundamentally different from diseases like diabetes (where prediabetes is detectable years in advance), Parkinson’s (where prodromal signs appear a decade or more before diagnosis), or stroke (where risk factors are modifiable for decades). GBM typically presents acutely — a seizure, a sudden headache, a new neurological symptom — and the tumor is already well-established by the time it becomes visible on imaging.

Why routine brain MRI screening is not recommended: MRI is expensive, has a high false-positive rate in healthy people (incidental findings that cause anxiety and unnecessary procedures), and GBM grows fast enough that even annual MRI would often miss the narrow window between invisible and symptomatic. The cost-benefit analysis does not support screening healthy people.

The vast majority of glioblastoma is sporadic — it arises from random mutations and is not inherited. Having one family member with GBM does not meaningfully increase risk for others. Most patients have no family history of brain tumors.

The rare exceptions:

Li-Fraumeni syndrome (TP53 mutations): A hereditary cancer predisposition syndrome that includes brain tumors among many cancer types. Families with multiple cancers across generations, especially at young ages, should discuss genetic counseling. Even in Li-Fraumeni, routine brain MRI surveillance is debated among experts and not universally recommended.
Neurofibromatosis type 1 (NF1): Slightly increased risk of certain brain tumors (usually low-grade gliomas, not GBM specifically).
Lynch syndrome / constitutional mismatch repair deficiency: Very rarely associated with brain tumors.

For most families of GBM patients: The children and siblings are not at meaningfully increased risk. The disease is not something to screen for in relatives. If there is an unusual clustering of cancers in the family across multiple generations, a genetic counselor at a cancer center is the right starting point — not a brain MRI.

If early population screening is not feasible, the next best thing is rapid evaluation when symptoms appear. The evidence is clear that smaller tumors at diagnosis are associated with better surgical outcomes and more treatment options. Days matter, not months.

Symptoms that warrant urgent evaluation:

New seizure in an adult (especially age 40+) with no prior seizure history
New, progressive headache pattern unlike any experienced before, especially with morning nausea
New weakness, speech difficulty, or personality change that does not resolve
New visual field loss or double vision

None of these symptoms means brain cancer — they have many common causes. But they mean get an MRI, not “wait and see.” The difference between a 2-cm and a 6-cm tumor at diagnosis can be the difference between a gross total resection and a biopsy-only outcome.

What a family can do: Know the symptoms. If a family member develops new, unexplained neurological symptoms, advocate for imaging. A normal result gives peace of mind. An abnormal result means treatment starts earlier — and earlier treatment is better treatment.

The honest bottom line: Glioblastoma is not a disease that rewards early screening in asymptomatic people. It is a disease that rewards speed once symptoms appear. Families should not live in fear of GBM or pursue routine brain imaging. They should know the warning signs and act without delay if any appear.

An Honest Word on Hope

Honest hope is not the same as optimism. It holds two truths at once: that the average outcome is shorter than anyone wants, and that a real minority of patients live much longer than average. Honest hope does the practical work the situation requires — legal documents, financial planning, difficult conversations — while pursuing every reasonable treatment option.

Common Features of Long-Term Survivors

Younger age at diagnosis
Good general health before diagnosis
Complete or near-complete surgical resection
MGMT promoter methylation
Access to a strong cancer center with active trials
Engagement with research and willingness to consider experimental approaches
Strong family and social support
Consistent adherence to maintenance treatment

Several of these factors are changeable. The strength of the cancer center, engagement with research, treatment adherence, and family support are all things this guide can help with.

Palliative care is not hospice. Palliative care runs alongside active cancer treatment from the very beginning, focused on symptom management. Studies show early palliative care actually extends survival. Engage it early.

Top 7 Priorities for the Next Six to Nine Months

Comprehensive molecular profiling — Full panel including the markers most people forget (H3 K27M, CMV, surface markers for CAR-T eligibility)
Optune at maximum compliance — Target above 90% wear time. Discuss CeTeG if MGMT-methylated.
The non-negotiable supportive layer — PCP prophylaxis, blood count monitoring, anti-nausea medication, PPI alternatives, blood clot awareness
Discuss diet and metabolic approach with your team — Ask about ketogenic or modified Atkins protocols under oncology dietitian supervision. Discuss repurposed drug literature (including mebendazole) with your neuro-oncologist.
Active trial enrollment — Screen for Gliofocus, GBM AGILE, EF-41/KEYNOTE D58, and others matched to molecular profile
Pre-written recurrence playbook by month 3 — Identify LITT centers, confirm trial eligibility, pre-contact international centers
The "free wins" — Steroid minimization, 30 minutes exercise 5-6 days/week, sleep protection, early palliative care

Questions to Ask Your Medical Team

What is the exact pathology diagnosis?
What molecular tests have been ordered? Will the panel include MGMT, IDH, BRAF V600E, NTRK, MTAP, H3 K27M, TMB, mismatch repair, surface markers?
Can the tumor tissue be stained for CMV?
What was the extent of resection on the post-operative MRI?
What is the proposed treatment plan? CeTeG if MGMT-methylated?
When will Optune start? Has authorization been initiated?
What clinical trials might this patient qualify for?
Is there any reason not to begin a ketogenic or modified Atkins diet?

What survival data are you quoting? Are those numbers from before or after Optune and CeTeG?
How will MRI monitoring be scheduled? Will perfusion imaging be included?
What is the second opinion strategy you would recommend?
Should we set up a baseline neuropsychological evaluation?
How do you handle urgent communication between appointments?

How will we tell true progression from pseudoprogression?
What salvage options are realistic at this center?
Is the patient a candidate for LITT + immunotherapy?
What CAR-T trials might apply based on tumor surface markers?
Should we consider ctDNA liquid biopsy monitoring?

What is the most realistic range of outcomes for this patient?
What can we do — beyond just receiving treatment — that actually makes a difference?
How do we know if and when to shift focus from active treatment to comfort-focused care?
Is there anything you wish more families would ask but usually don't?

Glossary

5-ALA (Gleolan): Substance taken before surgery that makes GBM cells glow under blue light, helping surgeons identify tumor tissue.
Astrocytoma: A brain tumor arising from astrocytes (star-shaped glial support cells). When IDH-mutant and grade 4, it is a distinct diagnosis from GBM with a generally better prognosis.
BBB (Blood-Brain Barrier): Tightly sealed cellular layer lining brain blood vessels. Keeps out most cancer drugs. Partially disrupted in the tumor core but intact in surrounding tissue where infiltrating cells hide.
Bevacizumab (Avastin): Drug that interferes with tumor blood vessel growth. Controls symptoms at recurrence but does not extend overall survival in trials.
CAR-T Cell Therapy: Patient’s own T-cells engineered in a laboratory to recognize and attack specific proteins on cancer cells.
CeTeG: Investigational intensified regimen adding lomustine to standard temozolomide for MGMT-methylated GBM. The NOA-09 trial showed a survival difference, but the regimen has not yet changed standard-of-care guidelines and involves increased toxicity. Discuss with your neuro-oncologist.
Contrast Enhancement: Bright areas on an MRI scan after gadolinium dye injection, indicating where the blood-brain barrier is broken down. Used to measure visible tumor size; does not show the full extent of infiltrating disease.
ctDNA: Circulating tumor DNA. Cancer cell DNA fragments found in blood or cerebrospinal fluid. Emerging monitoring tool.
Dexamethasone: A corticosteroid used to reduce brain swelling (edema) around the tumor. Effective but carries significant side effects with prolonged use including muscle wasting, mood changes, elevated blood sugar, and increased infection risk. Goal is the lowest effective dose.
FLAIR (Fluid-Attenuated Inversion Recovery): A type of MRI sequence that highlights abnormal signal in brain tissue while suppressing normal fluid. Shows the broader zone of tumor infiltration and edema beyond the contrast-enhancing core.
GBM (Glioblastoma): The most aggressive primary brain tumor, classified as WHO grade 4. Arises from glial cells (astrocytes). Characterized by rapid growth, invasive spread into surrounding brain tissue, and resistance to treatment. Approximately 12,000 new U.S. cases per year.
GKI (Glucose-Ketone Index): Blood glucose divided by blood ketones. Used to track ketosis depth. Target below 3, ideally below 2.
IDH Mutation: Changes the diagnosis to astrocytoma grade 4, a different disease with better prognosis and different treatment options.
IDH-Wildtype: A tumor without an IDH1 or IDH2 mutation. Most adult glioblastomas are IDH-wildtype, which is the more aggressive molecular subtype and the standard GBM diagnosis under current WHO classification.
Karnofsky Performance Status (KPS): A 0–100 scale measuring a patient’s ability to perform daily activities. 100 means fully functional; 70 means able to care for self but unable to work; scores below 60 indicate need for assistance. Used to determine treatment eligibility and predict outcomes.
LITT: Laser Interstitial Thermal Therapy. Laser-based tumor ablation that also opens the BBB in surrounding tissue.
MGMT Methylation: When the MGMT gene promoter is silenced (methylated), the tumor’s ability to repair chemotherapy-induced DNA damage is reduced, making temozolomide significantly more effective. Present in about 40–45% of GBMs. Key decision point for CeTeG.
Oligodendroglioma: A brain tumor arising from oligodendrocytes (myelin-producing glial cells). Defined by IDH mutation and 1p/19q co-deletion. A distinct diagnosis from GBM with a substantially better prognosis and different treatment approach.
Optune / TTFields (Tumor Treating Fields): Wearable device delivering low-intensity alternating electrical fields through scalp pads that disrupt cancer cell division. Added to maintenance chemotherapy after chemoradiation. Benefit appears dose-dependent on daily wear time.
Pseudoprogression: MRI changes mimicking tumor growth that are actually radiation-induced inflammation. Occurs in approximately 25% of patients. Distinguished using perfusion MRI, amino-acid PET, MR spectroscopy, or short-interval repeat imaging.
RANO Criteria (Response Assessment in Neuro-Oncology): Standardized rules used by neuro-oncologists to evaluate whether a brain tumor is responding to treatment, stable, or progressing. Based on contrast-enhancing tumor measurements, FLAIR changes, steroid dose, and clinical status.
Stupp Protocol: The standard-of-care treatment sequence for newly diagnosed GBM: maximal safe surgical resection, followed by six weeks of concurrent radiation and daily temozolomide, followed by maintenance temozolomide cycles. Named for Dr. Roger Stupp, whose 2005 trial established its value.
Temozolomide (TMZ, Temodar): An oral alkylating chemotherapy drug that crosses the blood-brain barrier. The backbone of GBM chemotherapy, used during radiation and in maintenance cycles afterward. Effectiveness is strongly influenced by MGMT methylation status.
WHO Grade 4: The highest grade in the World Health Organization brain tumor classification system. Indicates the most aggressive behavior: rapid growth, extensive blood vessel formation, areas of tissue death (necrosis), and high cell division rate. GBM is the most common WHO grade 4 brain tumor.

Specialty Neuro-Oncology Centers

No endorsement or affiliation. Listing here does not constitute a recommendation or endorsement of any center or physician. Trouvera has no financial relationship with any center listed. Information is based on publicly available data as of May 2026 and may change. Verify directly with each center.

The centers below are recognized for dedicated neuro-oncology programs with multidisciplinary brain tumor teams, active clinical trial portfolios, and subspecialty expertise relevant to glioblastoma.

Mountain West & Utah

Huntsman Cancer Institute — Neuro-Oncology Program

Salt Lake City, UT

NCI Comprehensive Cancer Center. Dedicated neuro-oncology clinic, proton therapy, GBM AGILE trial site, advanced surgical techniques including awake craniotomy and intraoperative MRI.

Neuro-Oncology: 801-585-7800 • General: 801-587-7000

University of Utah Health — Department of Neurosurgery

Salt Lake City, UT

Academic neurosurgery program with brain tumor subspecialty. Collaborates closely with Huntsman Cancer Institute for coordinated surgical and oncologic care.

Neurosurgery: 801-581-7575

Major U.S. National Centers

MD Anderson Cancer Center

Houston, TX

One of the largest brain and spine tumor programs in the world. Extensive clinical trial portfolio across all GBM treatment modalities.

New Patient: 877-632-6789 • Brain & Spine: 713-792-6600

Memorial Sloan Kettering Cancer Center

New York, NY

Comprehensive brain tumor center with dedicated neuro-oncology, neurosurgery, and neuroradiology teams. Major immunotherapy and targeted therapy research.

New Patient: 800-525-2225

Dana-Farber / Brigham Cancer Center

Boston, MA

Center for Neuro-Oncology. Major research and clinical trial program with expertise in molecular-guided treatment planning.

Phone: 877-442-3324

UCSF Brain Tumor Center

San Francisco, CA

Comprehensive neuro-oncology program with one of the largest active trial portfolios for brain tumors in the U.S.

Neuro-Oncology: 415-353-2966 • Neurosurgery: 415-353-7500

Duke Preston Robert Tisch Brain Tumor Center

Durham, NC

Pioneering immunotherapy, oncolytic virus research, and LITT programs. One of the longest-running dedicated brain tumor centers in the country.

Phone: 919-684-5301 • Screening: 866-385-3123

Veterans Services

VA Salt Lake City Health Care System — Oncology

Salt Lake City, UT

Oncology services for eligible veterans. Coordinates with Huntsman Cancer Institute for subspecialty neuro-oncology care and clinical trial access.

Main: 801-582-1565 • Toll-Free: 800-888-1770

Canada

Princess Margaret Cancer Centre

Toronto, ON, Canada

Part of University Health Network. One of the top five cancer research centers in the world. Glioblastoma clinical trials program with molecular profiling and immunotherapy research.

Phone: 416-946-2000

Sunnybrook Health Sciences Centre — Odette Cancer Centre

Toronto, ON, Canada

Leader in focused ultrasound BBB-opening research for brain tumors. Active MR-guided focused ultrasound program.

Phone: 416-480-6100

International

Charité — Universitätsmedizin Berlin

Berlin, Germany

One of Europe’s largest university hospitals. Neuro-oncology department with clinical trials, NanoTherm magnetic hyperthermia access, and expertise in recurrent glioma management.

International Office: +49 30 450 570 070

Gustave Roussy

Villejuif (Paris), France

Europe’s largest comprehensive cancer center. Active neuro-oncology program with clinical trials in immunotherapy, targeted therapy, and innovative radiation approaches for glioblastoma.

International: +33 1 42 11 42 11

UCL Queen Square Institute of Neurology — National Hospital for Neurology and Neurosurgery

London, United Kingdom

World-renowned neuroscience center. Neuro-oncology service with clinical trials and multidisciplinary brain tumor board. Part of University College London Hospitals NHS Foundation Trust.

Phone: +44 20 3456 7890

International treatment travel. Seeking care at an international center during serious illness carries clinical, financial, and logistical risks. Pre-contact international centers early while the patient is stable, obtain written cost estimates and eligibility confirmations, and discuss any international plan with your U.S. medical team before committing. See also: International Treatment Options.

Approaches that did not improve survival in GBM

Understanding what has not worked in GBM helps set realistic expectations for emerging treatments:

Bevacizumab (Avastin) in newly diagnosed GBM: Two large Phase 3 trials (AVAGLIO and RTOG 0825, both published 2014) showed bevacizumab added to standard Stupp chemoradiation improved progression-free survival but not overall survival, with worse quality of life in some patients. It remains used at recurrence for palliation and steroid-sparing but is not a first-line standard.
Rindopepimut (CDX-110), EGFRvIII peptide vaccine: ACT IV, a Phase 3 trial in EGFRvIII-positive GBM, showed no OS benefit vs. placebo and was terminated early (2016). EGFRvIII is also frequently downregulated or lost under treatment pressure.
Cilengitide (integrin inhibitor): A Phase 3 trial (CENTRIC) in MGMT-methylated GBM showed no benefit added to standard chemoradiation (2014). A non-methylated cohort trial also showed no benefit.
Most anti-VEGF and anti-EGFR agents as second-line: Cediranib, erlotinib, gefitinib, lapatinib, and sorafenib all failed to demonstrate meaningful OS benefit in randomized GBM trials despite preclinical rationale.
Immunotherapy (checkpoint inhibitors) in unselected GBM: CheckMate 498 (nivolumab vs. TMZ in unmethylated GBM) and CheckMate 548 (nivolumab + TMZ in methylated GBM) both failed to improve OS. GBM’s immunosuppressive microenvironment and relative lack of tumor mutation burden appear to limit PD-1/PD-L1 benefit in unselected patients.

Using Computational Tools in Your GBM Plan

Trouvera’s platform includes access to NaturaBridge, a pharmacological modeling engine that can perform several types of analyses relevant to GBM patients navigating complex medication and supplement regimens. These tools do not replace your medical team — all results are labeled as computational plausibility indicators, not clinical evidence — but they can help you formulate better questions and identify interactions worth discussing before making changes.

Computational outputs are not medical advice. Use these tools to prepare better-informed questions for your oncologist, not to make independent treatment decisions. Every medication change or supplement addition must be reviewed with your prescribing physician.

Herb-Drug Interaction Checking

GBM patients often navigate multiple medications simultaneously: dexamethasone, levetiracetam (or another anti-seizure medicine), temozolomide, PCP prophylaxis (trimethoprim-sulfamethoxazole or dapsone), and sometimes metformin, atorvastatin, or mebendazole from the repurposed drug discussion. Adding supplements to this stack without checking interactions is not safe.

NaturaBridge’s herb-drug interaction checker (accessible at trouvera.org) can screen a supplement or herbal product against your current medication list. Key examples of interactions relevant to GBM care:

St. John’s Wort + Temozolomide: Major interaction. St. John’s Wort strongly induces CYP3A4, reducing temozolomide plasma levels and potentially rendering chemotherapy less effective. NaturaBridge flags this as a HIGH-severity interaction.
Valerian + Levetiracetam: Additive CNS depression. Valerian is sometimes taken for sleep (relevant because dexamethasone causes insomnia), but the combination with levetiracetam can worsen sedation and cognitive effects.
High-dose Curcumin + Dexamethasone: Curcumin inhibits CYP3A4 and may affect dexamethasone metabolism. At supplement doses (as opposed to dietary amounts in food), this interaction is worth flagging to your team.
Echinacea + Immunotherapy: Echinacea is an immunostimulant. If you are enrolled in an immunotherapy trial (pembrolizumab, CAR-T, vaccine-based), discuss any immunostimulant supplement with your team first — the interaction with trial protocols is not well characterized.

Before adding any supplement, run a regimen safety check at trouvera.org. Bring the output to your oncologist appointment as a starting point for discussion.

Blood-Brain Barrier Penetration Modeling

The single most important question for any drug or supplement claimed to benefit GBM is: can it actually reach the tumor? A compound that does not cross the blood-brain barrier at meaningful concentrations cannot have a direct anti-tumor effect on cells deep in the brain, regardless of what laboratory studies show.

NaturaBridge includes a BBB penetration prediction model based on molecular structure. Inputs: the compound’s molecular formula or common name. Outputs: predicted CNS penetration probability (low / moderate / high) and predicted Cmax in brain tissue relative to plasma. This does not replace pharmacokinetic data from clinical studies — but for supplements or repurposed drugs with limited brain-specific pharmacokinetic data, it provides a preliminary plausibility check.

Compounds with consistently low predicted BBB penetration are unlikely to have meaningful direct anti-tumor effects in the brain, regardless of in vitro activity. This is important context for evaluating claims about natural supplements.

Drug Interaction Matrix for the Repurposed Drug Stack

For patients discussing the Care Oncology-style protocol (metformin, atorvastatin, mebendazole, and doxycycline alongside standard care), NaturaBridge can generate a full drug-drug interaction matrix checking each agent against the others and against standard GBM medications. Key interaction points to know about:

Metformin and temozolomide have no major pharmacokinetic interaction, but metformin can affect blood glucose (generally beneficial in this context, but requires monitoring if the patient develops hypoglycemia symptoms)
Atorvastatin is metabolized by CYP3A4; interactions with azole antifungals (sometimes used for PCP prophylaxis alternatives) can raise statin levels and increase myopathy risk
Mebendazole is also metabolized by CYP3A4 and CYP2C8; co-administration with strong CYP inducers (phenytoin, carbamazepine) can reduce mebendazole plasma levels — relevant if the patient is on older-generation anti-seizure medications
Doxycycline interacts with calcium, iron, and magnesium supplements (reduces antibiotic absorption); take at least 2 hours apart from any supplements containing these minerals

How to Access These Tools

Visit trouvera.org and navigate to the computational tools section. You will need to create a free account. Results are labeled as computational plausibility indicators and include references to the pharmacological literature supporting each prediction. Print or download interaction reports to share with your oncology team. If you have questions about a specific interaction result, contact the Trouvera team at the site or consult your neuro-oncologist directly.

Computational evidence badge: Any NaturaBridge output presented to your medical team should be clearly labeled as a computational prediction. These are hypothesis-generation tools, not clinical data. Your oncologist’s knowledge of your individual clinical situation takes precedence over any computational output.

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, and the work of physicians who treat GBM. Key sources include landmark clinical trials, major cancer center protocols, and peer-reviewed research available through PubMed (pubmed.ncbi.nlm.nih.gov) and ClinicalTrials.gov.

Primary Resources

PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
NCCN Guidelines for Clinicians (nccn.org) — Treatment guidelines followed by virtually every oncologist
NCCN Guidelines for Patients (nccn.org/patientresources) — Free, patient-friendly versions of the clinical guidelines
National Cancer Institute (NCI) (cancer.gov/types/brain) — Comprehensive brain tumor information
FDA MedWatch (fda.gov/medwatch) — Report adverse events from any medication or supplement
Society for Neuro-Oncology (soc-neuro-onc.org) — Professional society for brain tumor specialists
Central Brain Tumor Registry of the US (CBTRUS) (cbtrus.org) — Population-based incidence and survival statistics

Key Trials Referenced (May 2026 Update)

da Fonseca et al. — Intranasal perillyl alcohol in recurrent malignant glioma (198 patients). Anticancer Research 2013. PMID 24324108; PMC7879254
Twelves et al. — Nabiximols (Sativex) Phase 1b trial in recurrent GBM (12 vs. 9 in Part 2). British Journal of Cancer 2021. PMC8039032
Huang et al. — Disulfiram + copper Phase II/III RCT in newly diagnosed GBM (88 patients, negative result). JAMA Network Open March 2023. PMC10066460

External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site's privacy policy when you leave this site.

Major Brain Tumor Organizations

National Brain Tumor Society — braintumor.org, 800-934-2873
American Brain Tumor Association — abta.org, 800-886-2282
Musella Foundation — virtualtrials.org, 888-295-4740
Brain Tumor Network — braintumornetwork.org
CancerCare — cancercare.org, 800-813-4673 (financial assistance grants)
Patient Advocate Foundation — patientadvocate.org, 800-532-5274

A practical test for any online claim: If a website is making a claim about GBM treatment that does not appear anywhere in PubMed or NCCN guidelines, that should be a significant warning sign. The major medical bodies do not miss treatments that work.

Updated Information

Changes and additions since this guide was first published. Newest updates appear first. Each update is also reflected in the relevant section of the guide above.

07 Jul 2026 New Major enrichment: 8 new sections added — First Seven Days day-by-day checklist; Optune EF-14 compliance data (24.9 vs 13.5 months by wear tier); expanded steroid-minimization section (glucose/immune mechanisms, Boswellia, PPI alternatives); repurposed drugs exclusion list (disulfiram negative RCT, HCQ retinal toxicity); new Liquid Biopsy & ctDNA section; recurrence playbook template; Goals of Care / palliative care section; expanded international options with BNCT mechanism and Germany iMDT access; Computational Tools section. Go to First Seven Days →
26 May 2026 New Emerging Research & Negative Results section added — Three verified international research findings: intranasal perillyl alcohol (Brazilian program, 198 patients), nabiximols/Sativex Phase 1b trial, and disulfiram + copper Phase II/III RCT (negative result). Go to section →
26 May 2026 Trial Disulfiram + copper RCT — negative result documented — Phase II/III trial (88 patients, JAMA Network Open 2023) showed no survival benefit with increased adverse events. Added as explicit warning. Go to section →
21 May 2026 New Early Detection & Family Risk section added — Honest assessment of GBM screening (not feasible for most), inherited risk (Li-Fraumeni, NF1), and what does help: acting fast when symptoms appear. Go to section →
21 May 2026 Correction Worldwide incidence figure corrected — Changed from “250,000 annually” (which included all primary brain tumors) to a more accurate estimate of 150,000–200,000 GBM cases specifically. Go to section →

A Research Guide forFacing Glioblastoma

⚡ Quick Start — If You Read Nothing Else

Understanding Glioblastoma

Why Glioblastoma Is Especially Difficult

Molecular Markers: The Map That Personalizes Treatment

Key Markers to Request

The First Weeks After Diagnosis

What Matters Most Right Now

Standard Treatment: The Foundation

Surgery: Understanding What Was Done

Questions to Discuss with the Surgical Team

Chemoradiation: The Stupp Protocol

What to Expect

Common Side Effects

If MGMT Is Methylated: The CeTeG Discussion

Essential Supportive Care During Chemoradiation

Tumor Treating Fields (Optune)

The Compliance Data That Changes How to Think About Optune

Practical Compliance Tips

Additional Practical Details

Steroid Management

Why Steroid Minimization Is a Treatment Strategy, Not Just Side-Effect Management

Boswellia as a Steroid-Sparing Adjunct

A Note on Proton Pump Inhibitors (PPIs)

Symptoms That Warrant Calling Your Team About Steroids

Seizure Medications

The Blood-Brain Barrier Problem

Three Strategies for Getting Around the BBB

Three Phases of Treatment

Phase 1: Immediate (Post-Surgery through Start of Chemoradiation)

Phase 2: Short-Term (Months 1-3)

Phase 3: Medium-Term (Months 3-9+)

The First Seven Days: A Day-by-Day Checklist

Days 1–2: In the Hospital After Surgery

Days 3–5: Before or Just After Hospital Discharge

Week 1 (Days 5–7): Home and Active Planning

Weeks 2–3: Legal, Logistical, and Clinical Planning

Pre-Chemoradiation Action Checklist

Diet and Metabolic Strategy

Practical Implementation Points

Exercise

Sleep and Circadian Rhythm

Candidates Worth Discussing with Your Medical Team

Emerging Research & Negative Results

Tissue Banking and Growing the Tumor Outside the Body

What Banked Tissue Can Enable

Liquid Biopsy and ctDNA Monitoring

The GBM-Specific Challenge

CSF ctDNA: More Sensitive, More Invasive

Guardant360 and Other Commercial Platforms

When Liquid Biopsy Is Clinically Useful in GBM

The Future of ctDNA in GBM

The Molecular Decision Tree

Most Common Scenarios

Clinical Trials: A Treatment Option, Not a Last Resort

Key Trials to Ask About (2026)

How to Search for Trials

Patient Navigation Services

Pregnancy and Glioblastoma

Questions to Ask Your Doctor

If the Tumor Returns

Your Recurrence Playbook Template

Step 1: Confirm True Progression vs. Pseudoprogression

Step 2: Repeat Molecular Testing

Step 3: Salvage Pathway Options (Discuss with Medical Team)

Decision Triggers — When to Act

Major Brain Tumor Centers by Region

UCSF Brain Tumor Center

Stanford Health Care

City of Hope

UCLA Brain Tumor Center

Huntsman Cancer Institute

Mayo Clinic — Phoenix

Ivy Brain Tumor Center at Barrow Neurological Institute

MD Anderson Cancer Center

Northwestern Memorial Hospital

Washington University in St. Louis

Cleveland Clinic

Mayo Clinic — Rochester

Henry Ford Hermelin Brain Tumor Center

A Research Guide for
Facing Glioblastoma